API

Key Events

Id Title Short name Biological organization
3 Reduction, 17beta-estradiol synthesis by ovarian granulosa cells Reduction, 17beta-estradiol synthesis by ovarian granulosa cells Cellular
8 Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity Cellular
10 Acetylcholine accumulation in synapses ACh Synaptic Accumulation Cellular
12 Acetylcholinesterase (AchE) Inhibition AchE Inhibition Cellular
21 Altered regulation, Alpha hemoglobin Altered regulation, Alpha hemoglobin Cellular
35 Decrease, Aromatase (Cyp19a1) Decrease, Aromatase (Cyp19a1) Cellular
40 Decrease, Mitochondrial ATP production Decrease, Mitochondrial ATP production Cellular
46 Accumulation, Biological membranes Accumulation, Biological membranes Cellular
50 Increase, Ca++ (intracellular) Increase, Ca++ (intracellular) Cellular
52 Decreased, Calcium influx Decreased, Calcium influx Cellular
55 Cell injury/death Cell injury/death Cellular
57 Proliferation, Cell proliferation in the absence of cytotoxicity Proliferation, Cell proliferation in the absence of cytotoxicity Cellular
64 Reduction, Ionotropic GABA receptor chloride channel conductance Reduction, Ionotropic GABA receptor chloride channel conductance Cellular
77 Production, Critical Metabolites (CGA 330050 and CGA 265307) Production, Critical Metabolites (CGA 330050 and CGA 265307) Cellular
87 Release, Cytokine Release, Cytokine Cellular
89 Synthesis, De Novo FA Synthesis, De Novo FA Cellular
110 Impairment, Endothelial network Impairment, Endothelial network Cellular
115 Increase, FA Influx Increase, FA Influx Cellular
118 Formation, Formation of hemoglobin adducts Formation, Formation of hemoglobin adducts Cellular
130 Depletion, GSH Depletion, GSH Cellular
131 Down Regulation, Gulcose-6-phosphate dehydrogenase Down Regulation, Gulcose-6-phosphate dehydrogenase Cellular
134 Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) Cellular
140 Decreased, HSD17B10 expression Decreased, HSD17B10 expression Cellular
145 Induction, IKB inhibitory protein Induction, IKB inhibitory protein Cellular
147 Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307 Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307 Cellular
149 Increase, Inflammation Increase, Inflammation Cellular
155 Inadequate DNA repair Inadequate DNA repair Cellular
158 N/A, Interferences with SH-/selen-proteins N/A, Interferences with SH-/selen-proteins Cellular
165 Activation, Long term AHR receptor driven direct and indirect gene expression changes Activation, Long term AHR receptor driven direct and indirect gene expression changes Cellular
169 Disruption, Membrane integrity Disruption, Membrane integrity Cellular
176 Damaging, Mitochondria Damaging, Mitochondria Cellular
177 N/A, Mitochondrial dysfunction 1 N/A, Mitochondrial dysfunction 1 Cellular
178 Disruption, Mitochondrial electron transport chain Disruption, Mitochondrial electron transport chain Cellular
191 Neuronal dysfunction Neuronal dysfunction Cellular
193 Decreased, Nitric Oxide Decreased, Nitric Oxide Cellular
210 N/A, Oxidative stress N/A, Oxidative stress Cellular
214 Bile accumulation, Pathological condition Bile accumulation, Pathological condition Cellular
216 Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway) Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway) Cellular
250 Damaging, Red blood cells; hemolysis Damaging, Red blood cells; hemolysis Cellular
265 Activation, Stellate cells Activation, Stellate cells Cellular
266 Decrease, Steroidogenic acute regulatory protein (STAR) Decrease, Steroidogenic acute regulatory protein (STAR) Cellular
269 Induction, Sustained Cell Proliferation Induction, Sustained Cell Proliferation Cellular
274 Reduction, Testosterone synthesis by ovarian theca cells Reduction, Testosterone synthesis by ovarian theca cells Cellular
276 Up Regulation, TGFbeta1 expression Up Regulation, TGFbeta1 expression Cellular
277 Thyroid hormone synthesis, Decreased TH synthesis, Decreased Cellular
288 Activation of specific nuclear receptors, Transcriptional change Activation of specific nuclear receptors, Transcriptional change Cellular
289 Decrease, Translocator protein (TSPO) Decrease, Translocator protein (TSPO) Cellular
291 Accumulation, Triglyceride Accumulation, Triglyceride Cellular
309 Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development Cellular
310 Alteration, Wnt pathway Alteration, Wnt pathway Cellular
376 Increased, Induced Mutations in Critical Genes Increased, Induced Mutations in Critical Genes Cellular
382 Aberrant, Dendritic morphology Aberrant, Dendritic morphology Cellular
385 Decrease of synaptogenesis Synaptogenesis, Decreased Cellular
388 Overactivation, NMDARs Overactivation, NMDARs Cellular
389 Increased, Intracellular Calcium overload Increased, Intracellular Calcium overload Cellular
397 Response, Keratinocytes Response, Keratinocytes Cellular
398 Activation, Dendritic Cells Activation, Dendritic Cells Cellular
408 reduction in ovarian granulosa cells, Aromatase (Cyp19a1) reduction in ovarian granulosa cells, Aromatase (Cyp19a1) Cellular
413 Reduction, Testosterone synthesis in Leydig cells Reduction, Testosterone synthesis in Leydig cells Cellular
414 Increase, Luteinizing hormone (LH) Increase, Luteinizing hormone (LH) Cellular
415 Hyperplasia, Leydig cell Hyperplasia, Leydig cell Cellular
416 Increase proliferation, Leydig cell Increase proliferation, Leydig cell Cellular
418 Increased, Vitellogenin synthesis Increased, Vitellogenin synthesis Cellular
425 Decrease of Thyroidal iodide Thyroidal Iodide, Decreased Cellular
427 Down Regulation, K-Cl co-transporter 2 (KCC2) Down Regulation, K-Cl co-transporter 2 (KCC2) Cellular
428 Delay, Developmental GABA shift Delay, Developmental GABA shift Cellular
447 Reduction, Cholesterol transport in mitochondria Reduction, Cholesterol transport in mitochondria Cellular
450 Suppression, VLDL secretion Suppression, VLDL secretion Cellular
454 Increased, Triglyceride formation Increased, Triglyceride formation Cellular
458 Increased, De Novo FA synthesis Increased, De Novo FA synthesis Cellular
460 Increased, Fatty acid uptake Increased, Fatty acid uptake Cellular
465 Increased, FA Influx Increased, FA Influx Cellular
467 Increased, LDL uptake Increased, LDL uptake Cellular
477 Decreased, Ketogenesis Decreased, Ketogenesis Cellular
495 Repressed expression of steroidogenic enzymes Repressed expression of steroidogenic enzymes Cellular
496 Increased apoptosis, decreased fetal/adult Leydig Cells Decreased Leydig Cells Cellular
525 Apoptosis of adult Leydig cells, Decreased testosterone by adult Leydig cells Apoptosis of adult Leydig cells, Decreased testosterone by adult Leydig cells Cellular
528 Decreased, Synthesis of NE Decreased, Synthesis of NE Cellular
530 Decreased, GnRH pulsatility/release Decreased, GnRH pulsatility/release Cellular
531 Decreased, LH Surge Decreased, LH Surge Cellular
533 Decreased, Cortical granule release/distribution upon fertilization Decreased, Cortical granule release/distribution upon fertilization Cellular
534 Altered, Formation of cortical envelope Altered, Formation of cortical envelope Cellular
535 Abnormal, Sperm penetration (polyspermy) Abnormal, Sperm penetration (polyspermy) Cellular
536 Altered, Chromosome number (polyploid) zygote Altered, Chromosome number (polyploid) zygote Cellular
541 Decreased testosterone by the fetal Leydig cells, Decreased COUP-TFII stem Leydig cells Decreased testosterone by the fetal Leydig cells, Decreased COUP-TFII stem Leydig cells Cellular
570 Accumulation, Damaged mitochondrial DNA Accumulation, Damaged mitochondrial DNA Cellular
585 Decreased, Sodium conductance 1 Decreased, Sodium conductance 1 Cellular
599 prolonged, Depolarization of neuronal membrane prolonged, Depolarization of neuronal membrane Cellular
626 Increased, serotonin (5-HT) Increased, serotonin (5-HT) Cellular
633 Decrease, histaminergic neuron excitation Decrease, histaminergic neuron excitation Cellular
645 Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells Cellular
647 Decreased steroidogenesis, Decreased Activity of Steroidogenic Enzymes in Adult Leydig cells Decreased steroidogenesis, Decreased Activity of Steroidogenic Enzymes in Adult Leydig cell Cellular
651 Glucocorticoid Receptor mediated alterations in steriodogenic enzymes, Decreased testosterone by adult Leydig cells Glucocorticoid Receptor mediated alterations in steriodogenic enzymes, Decreased testostero Cellular
652 Direct effects of Corticosterone on steroidogenesis, Decreased testosterone by adult Leydig cells Direct effects of Corticosterone on steroidogenesis, Decreased testosterone by adult Leydig Cellular
653 Decreased testosterone by the fetal Leydig cells, Increased corticosterone Decreased testosterone by the fetal Leydig cells, Increased corticosterone Cellular
654 Decreased testosterone by the fetal Leydig cells, Activation by other glucocorticoid receptor agonists Decreased testosterone by the fetal Leydig cells, Activation by other glucocorticoid recept Cellular
655 Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells Cellular
656 Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells Cellular
658 Decreased testosterone by the fetal Leydig cells, Increased estradiol Decreased testosterone by the fetal Leydig cells, Increased estradiol Cellular
659 Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists Cellular
664 Overwhelmed, Mitochondrial DNA repair mechanisms Overwhelmed, Mitochondrial DNA repair mechanisms Cellular
669 Reduction, Neuronal synaptic inhibition Reduction, Neuronal synaptic inhibition Cellular
682 Generation, Amplified excitatory postsynaptic potential (EPSP) Generation, Amplified excitatory postsynaptic potential (EPSP) Cellular
694 Reduced, Meiotic prophase I/metaphase I transition, oocyte Reduced, Meiotic prophase I/metaphase I transition, oocyte Cellular
696 Increased, Chromosome misseggregation Increased, Chromosome misseggregation Cellular
697 impaired, ion channels impaired, ion channels Cellular
698 Altered, Action Potential Altered, Action Potential Cellular
709 Increase, Cytotoxicity (renal tubular cell) Increase, Cytotoxicity (renal tubular cell) Cellular
710 Increase, Regenerative cell proliferation (tubular epithelial cells) Increase, Regenerative cell proliferation (tubular epithelial cells) Cellular
716 Increase, cell proliferation (hepatocytes) Increase, cell proliferation (hepatocytes) Cellular
721 Disorganization, Meiotic Spindle Disorganization, Meiotic Spindle Cellular
723 Altered, Chromosome number Altered, Chromosome number Cellular
724 Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme Cellular
733 Increase, Necrosis (terminal bronchiolar cells) Increase, Necrosis (terminal bronchiolar cells) Cellular
734 Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) Cellular
735 Increase, Hyperplasia (terminal bronchiolar cells) Increase, Hyperplasia (terminal bronchiolar cells) Cellular
737 Decreased, Uptake of inorganic iodide Decreased, Uptake of inorganic iodide Cellular
739 Increase, Hypertrophy and proliferation (follicular cell) Increase, Hypertrophy and proliferation (follicular cell) Cellular
740 Increase, Hyperplasia (follicular cells) Increase, Hyperplasia (follicular cells) Cellular
744 Increase, Hyperplasia (Leydig cells) Increase, Hyperplasia (Leydig cells) Cellular
745 Increase, Leydig cell tumors Increase, Leydig cell tumors Cellular
746 Increase, Dopaminergic activity Increase, Dopaminergic activity Cellular
752 Altered, Meiotic chromosome dynamics Altered, Meiotic chromosome dynamics Cellular
761 Increased, Chloride conductance Increased, Chloride conductance Cellular
763 hyperpolarisation, neuron hyperpolarisation, neuron Cellular
767 Increase, Hyperplasia (renal tubular cells) Increase, Hyperplasia (renal tubular cells) Cellular
768 Increase, Cytotoxicity Increase, Cytotoxicity Cellular
769 Increase, Oxidative metabolism Increase, Oxidative metabolism Cellular
770 Increase, Cytotoxicity (club cells) Increase, Cytotoxicity (club cells) Cellular
772 Increase, Hyperplasia (glandular epithelial cells of endometrium) Increase, Hyperplasia (glandular epithelial cells of endometrium) Cellular
774 Increase, Preneoplastic foci (hepatocytes) Increase, Preneoplastic foci (hepatocytes) Cellular
776 Increase, Cytotoxicity (corneal cells) Increase, Cytotoxicity (corneal cells) Cellular
777 Increase, Inflammation (corneal cells) Increase, Inflammation (corneal cells) Cellular
778 Increase, Regenerative cell proliferation (corneal cells) Increase, Regenerative cell proliferation (corneal cells) Cellular
779 Increase, Papillomas/carcinomas (squamous cells) Increase, Papillomas/carcinomas (squamous cells) Cellular
780 Increase, Cytotoxicity (epithelial cells) Increase, Cytotoxicity (epithelial cells) Cellular
781 Increase, Regenerative cell proliferation (forestomach epithelial cells) Increase, Regenerative cell proliferation (forestomach epithelial cells) Cellular
782 Increase, Hyperplasia (forestomach epithelial cells) Increase, Hyperplasia (forestomach epithelial cells) Cellular
783 Increase, Cytotoxicity (tubular epithelial cells) Increase, Cytotoxicity (tubular epithelial cells) Cellular
784 Increase, Hyperplasia (tubular epithelial cells) Increase, Hyperplasia (tubular epithelial cells) Cellular
786 Increase, Cytotoxicity (hepatocytes) Increase, Cytotoxicity (hepatocytes) Cellular
787 Increase, Regenerative cell proliferation (hepatocytes) Increase, Regenerative cell proliferation (hepatocytes) Cellular
788 Decrease, Incorporation of active iodide into iodotyrosines Decrease, Incorporation of active iodide into iodotyrosines Cellular
790 Inhibition, 5α-reductase activity Inhibition, 5α-reductase activity Cellular
794 Increase, Cytotoxicity (urothelial cells) Increase, Cytotoxicity (urothelial cells) Cellular
795 Increase, Regenerative cell proliferation (urothelial cells) Increase, Regenerative cell proliferation (urothelial cells) Cellular
796 Increase, Hyperplasia (urothelial) Increase, Hyperplasia (urothelial) Cellular
798 Inhibition, Prolyl hydroxylases Inhibition, Prolyl hydroxylases Cellular
799 Increased, HIF-1 heterodimer Increased, HIF-1 heterodimer Cellular
800 Decreased, Aromatase (Cyp19a1) mRNA Decreased, Aromatase (Cyp19a1) mRNA Cellular
802 Increased, HIF-1 alpha transcription Increased, HIF-1 alpha transcription Cellular
804 Inhibition, HMG-CoA reductase Inhibition, HMG-CoA reductase Cellular
805 Decreased, mevalonate Decreased, mevalonate Cellular
826 Activation, Keratinocytes Activation, Keratinocytes Cellular
829 Damage, Lipid bilayer Damage, Lipid bilayer Cellular
831 Disturbance, Lysosomal function Disturbance, Lysosomal function Cellular
832 Injury, Mitochondria Injury, Mitochondria Cellular
833 Occurrence, Cytoplasmic vacuolization (hepatocyte) Occurrence, Cytoplasmic vacuolization (hepatocyte) Cellular
835 Occurrence, Ballooning degeneration (hepatocyte) Occurrence, Ballooning degeneration (hepatocyte) Cellular
836 Occurrence, Cytoplasmic vacuolization (Bile duct cell) Occurrence, Cytoplasmic vacuolization (Bile duct cell) Cellular
837 Occurrence, Cytoplasmic vacuolization (kupffer cell) Occurrence, Cytoplasmic vacuolization (kupffer cell) Cellular
839 Formation, Mallory body Formation, Mallory body Cellular
844 Oxidation, Uroporphyrinogen Oxidation, Uroporphyrinogen Cellular
848 Decreased, Binding of NE to NE receptors on GnRH neurons Decreased, Binding of NE to NE receptors on GnRH neurons Cellular
851 Decrease of GABAergic interneurons GABAergic interneurons, Decreased Cellular
853 Changes/Inhibition, Cellular Homeostasis and Apoptosis Changes/Inhibition, Cellular Homeostasis and Apoptosis Cellular
861 Decreased, Ketogenesis (production of ketone bodies) Decreased, Ketogenesis (production of ketone bodies) Cellular
867 Decrease, Intracellular pH Decrease, Intracellular pH Cellular
870 Increase, Cell Proliferation Increase, Cell Proliferation Cellular
879 Activation, MTTP Activation, MTTP Cellular
881 Increased, Triglyceride Increased, Triglyceride Cellular
887 Inhibition, NADH-ubiquinone oxidoreductase (complex I) Inhibition, NADH-ubiquinone oxidoreductase (complex I) Cellular
889 Impaired, Proteostasis Impaired, Proteostasis Cellular
898 Disruption, Lysosome Disruption, Lysosome Cellular
914 Decrease, Apoptosis of ciliated epithelial cells Decreased ciliated cell apoptosis Cellular
919 Occurrence, Transdifferentiation of ciliated epithelial cells Occurrence, Transdifferentiation of ciliated epithelial cells Cellular
923 Increase, Proliferation of goblet cells Increased goblet cell proliferation Cellular
932 KE4 : Uncoupling, eNOS Uncoupling, eNOS Cellular
933 KE6 : Depletion, Nitric Oxide Depletion, Nitric Oxide Cellular
934 KE3 : Decrease, Tetrahydrobiopterin Decrease, Tetrahydrobiopterin Cellular
935 KE2 : Decrease, GTPCH-1 Decrease, GTPCH-1 Cellular
948 reduced production, VEGF reduced production, VEGF Cellular
960 Increased, Uptake of thyroxine into tissue Increased, Uptake of thyroxine into tissue Cellular
962 Increase, Mucin production Increase, Mucin production Cellular
965 reduction in ovarian granulosa cells synthesis of estradiol, Reduced steroidogenic production of estradiol in granulosa cells reduction in ovarian granulosa cells synthesis of estradiol, Reduced steroidogenic producti Cellular
968 Decreased Kisspeptin release from neurons in AVPV, Decreased hypothalamic estrogen reduces kisspeptinergic neuron response Decreased Kisspeptin release from neurons in AVPV, Decreased hypothalamic estrogen reduces Cellular
969 Decreased GnRH Release, Decreased Kisspeptin stimulation of GnRH neurons Decreased GnRH Release, Decreased Kisspeptin stimulation of GnRH neurons Cellular
970 Decreased LH release from Anterior Pituitary, Decreased GnRH stimulation of Anterior Pituitary Gonadotrophs Decreased LH release from Anterior Pituitary, Decreased GnRH stimulation of Anterior Pituit Cellular
973 KE5 : Decrease, AKT/eNOS activity Decrease, AKT/eNOS activity Cellular
981 Reduction, NFAT/AP-1 complex formation Reduction, NFAT/AP-1 complex formation Cellular
982 Suppression, Suppression in mixed lymphocyte reaction (MLR) Suppression, Suppression in mixed lymphocyte reaction (MLR) Cellular
983 Suppression, Suppression of T-cell dependent antibody response (TDAR) Suppression, Suppression of T-cell dependent antibody response (TDAR) Cellular
1012 Increased, Inhibitory postsynaptic potential Increased, Inhibitory postsynaptic potential Cellular
1015 Increased, Neuronal synaptic inhibition Increased, Neuronal synaptic inhibition Cellular
1020 Increased, induction of UDPGT's in liver Increased, induction of UDPGT's in liver Cellular
1021 Increased, T4/T3 catabolism Increased, T4/T3 catabolism Cellular
1024 Increased, Hypertrophy and proliferation (follicular cell) Increased, Hypertrophy and proliferation (follicular cell) Cellular
1029 Increased, adipogenesis Increased, adipogenesis Cellular
1032 Increased, secretion of local growth factors Increased, secretion of local growth factors Cellular
1033 Increased, proliferation of mesenchymal cells Increased, proliferation of mesenchymal cells Cellular
1034 Increased, IGF-1 (mouse) Increased, IGF-1 (mouse) Cellular
1042 Proliferation/Clonal Expansion, smooth muscle Proliferation/Clonal Expansion, smooth muscle Cellular
1043 Hypertrophy/hyperplasia, smooth muscle Hypertrophy/hyperplasia, smooth muscle Cellular
1047 Increased, secretion of GnRH from hypothalamus Increased, secretion of GnRH from hypothalamus Cellular
1049 Increased, secrection of FSH from anterior pituitary Increased, secrection of FSH from anterior pituitary Cellular
1050 Increased, secretion of LH from anterior pituitary Increased, secretion of LH from anterior pituitary Cellular
1051 Hyperplasia, ovarian stromal cells Hyperplasia, ovarian stromal cells Cellular
1054 Promotion, ovarian granular cell tumors Promotion, ovarian granular cell tumors Cellular
1060 Alteration, lipid metabolism Alteration, lipid metabolism Cellular
1062 Increased, Cellular proliferation / hyperplasia of acinar cells Increased, Cellular proliferation / hyperplasia of acinar cells Cellular
1066 Promotion, SIX-1 postive basal-type progenitor cells Promotion, SIX-1 postive basal-type progenitor cells Cellular
1067 Proliferation/Clonal Expansion, aberrant basal cells Proliferation/Clonal Expansion, aberrant basal cells Cellular
1069 Increased, Hyperplasia (glandular epithelial cells of endometrium) Increased, Hyperplasia (glandular epithelial cells of endometrium) Cellular
1071 Decreased, GnRH pulsatility/release in hypothalamus Decreased, GnRH pulsatility/release in hypothalamus Cellular
1072 Decreased, LH Surge from anterior pituitary Decreased, LH Surge from anterior pituitary Cellular
1081 Increased, lactotroph hyperplasia and hypertrophy Increased, lactotroph hyperplasia and hypertrophy Cellular
1083 Decreased, Dopaminergic activity Decreased, Dopaminergic activity Cellular
1086 persistent, cytotoxicity (pleura or peritoneum) persistent, cytotoxicity (pleura or peritoneum) Cellular
1087 Increased, inflammation Increased, inflammation Cellular
1089 Increased, Cell Proliferation (mesothelium) Increased, Cell Proliferation (mesothelium) Cellular
1115 Increased, Reactive oxygen species Increased, Reactive oxygen species Cellular
1132 Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis Cellular
1162 Increased, cilia movement Increased, cilia movement Cellular
1170 Increase, Phenotypic enzyme activity Increase, Phenotypic enzyme activity Cellular
1171 Increase, Clonal Expansion of Altered Hepatic Foci Increase, Clonal Expansion of Altered Hepatic Foci Cellular
1172 Increased activation, Nuclear factor kappa B (NF-kB) Increased activation, Nuclear factor kappa B (NF-kB) Cellular
1175 Increase, Genes involved in fatty acid oxidation Increase, Genes involved in fatty acid oxidation Cellular
1176 Decreased, sodium conductance 2 Decreased, sodium conductance 2 Cellular
1177 Decreased, Ionotropic GABA receptor chloride channel conductance Decreased, Ionotropic GABA receptor chloride channel conductance Cellular
1179 Decreased, GABA release Decreased, GABA release Cellular
1182 Increase, Cell Proliferation (Epithelial Cells) Increase, Cell Proliferation (Epithelial Cells) Cellular
1183 Decreased, Apoptosis (Epithelial Cells) Decreased, Apoptosis (Epithelial Cells) Cellular
1189 Increased, Proliferation (Endothelial cells) Increased, Proliferation (Endothelial cells) Cellular
1190 Increased, Migration (Endothelial Cells) Increased, Migration (Endothelial Cells) Cellular
1191 Increased, Non-genomic signaling Increased, Non-genomic signaling Cellular
1195 modulation, Extracellular Matrix Composition modulation, Extracellular Matrix Composition Cellular
1196 Increased, Invasion Increased, Invasion Cellular
1197 Activation, Fibroblasts Activation, Fibroblasts Cellular
1198 Activation, Macrophages Activation, Macrophages Cellular
1202 Suppression, IL-2 and IL-4 production Suppression, IL-2 and IL-4 production Cellular
1204 Suppression, Suppression of T-cell dependent antibody production Suppression, Suppression of T-cell dependent antibody production Cellular
1212 Reduced, Neuronal synaptic inhibition Reduced, Neuronal synaptic inhibition Cellular
1213 Increased, Angiogenesis Increased, Angiogenesis Cellular
1214 Altered gene expression specific to CAR activation, Hepatocytes Altered expression of hepatic CAR-dependent genes Cellular
1218 Opening of calcium channel, Calcium influx Opening of calcium channel, Calcium influx Cellular
1222 SP (Substance P) release, Local increase of SP SP (Substance P) release, Local increase of SP Cellular
1236 Generation of novel epitopes , Antigen presentation Generation of novel epitopes , Antigen presentation Cellular
1240 Altered, Protein Production Altered, Protein Production Cellular
1241 Increased, Motility Increased, Motility Cellular
1242 Increased, Second Messenger Production Increased, Second Messenger Production Cellular
1243 Altered, Ca2+-calmodulin activated signal transduction Altered, Ca2+-calmodulin activated signal transduction Cellular
1253 MLL chromosomal translocation MLL translocation Cellular
1258 Decompartmentalization Decompartmentalization Cellular
1259 narcosis narcosis Cellular
1262 Apoptosis Apoptosis Cellular
1271 Activation of TGF-β signaling Activation of TGF-β signaling Cellular
1272 Differentiation of Myofibroblast Differentiation of Myofibroblast Cellular
1273 Expression of Collagen Expression of Collagen Cellular
1274 Production of α-smooth muscle actin Production of α-smooth muscle actin Cellular
1279 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK Cellular
1280 Activation, HIF-1 Activation, HIF-1 Cellular
1281 Increased, DNA Damage-Repair Increased, DNA Damage-Repair Cellular
1282 Activation, JAK/STAT pathway Activation, JAK/STAT pathway Cellular
1283 Activation, TGF-beta pathway Activation, TGF-beta pathway Cellular
1284 Up Regulation, SREBF2 Up Regulation, SREBF2 Cellular
1285 Up Regulation, Unsaturated fatty acid Up Regulation, Unsaturated fatty acid Cellular
1286 Down Regulation, GSS and GSTs gene Down Regulation, GSS and GSTs gene Cellular
1287 Glutathione synthesis Glutathione synthesis Cellular
1288 Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene Cellular
1289 Perturbation of cholesterol Perturbation of cholesterol Cellular
1290 Glutathione homeostasis Glutathione homeostasis Cellular
1291 Hepatotoxicity Hepatotoxicity Cellular
1292 Activation, JNK Activation, JNK Cellular
1293 Activation, FOXO Activation, FOXO Cellular
1294 Inhibition, Wnt pathway Inhibition, Wnt pathway Cellular
1305 Increase, cytosolic fatty acid Increase, cytosolic fatty acid Cellular
1312 Increase, Fatty acid beta-oxidation Increase, Fatty acid β-oxidation Cellular
1339 Increase, intracellular calcium Increase, intracellular calcium Cellular
1355 Activated, membrane depolarization Activated, membrane depolarization Cellular
1365 Increase, Apoptosis Increase, Apoptosis Cellular
1379 Activate, leukocyte Activate, leukocyte Cellular
1387 7α-hydroxypregnenolone synthesis in the brain, decreased 7α-hydroxypregnenolone synthesis in the brain, decreased Cellular
1393 Hepatocytotoxicity Hepatocytotoxicity Cellular
1394 Induction, persistent proliferation/sustained proliferation Sustained proliferation Cellular
1397 Increased, serotonin transporter activity Increased, serotonin transporter activity Cellular
1398 Increased, intracellular serotonin Increased, intracellular serotonin Cellular
1399 Increased, packaged serotonin Increased, packaged serotonin Cellular
1400 Increased, synaptic release Increased, synaptic release Cellular
1408 Reduced, PTGS2 function Reduced, PTGS2 function Cellular
1413 Reduced, presynaptic neuron 2 activity Reduced, presynaptic neuron 2 activity Cellular
1414 Decreased, GABA Decreased, GABA Cellular
1416 Decreased, intracellular chloride Decreased, intracellular chloride Cellular
1426 Release of G Proteins Release of G Proteins Cellular
1427 Opening of G protein gated inward rectifying K channels Opening of GIRK channels Cellular
1429 Inhibition of N-type Ca ion channels Inhibition of Ca Channels Cellular
1430 Inhibition of neurotransmitter vesicle release Inhibition of neurotransmitter release Cellular
1433 Increased CGRP, neuronal release of CGRP Increased CGRP Cellular
1435 Increased neurokinin A (NKA) by neuronal cells Increased NKA Cellular
1436 neurogenic inflammation of sensory nerves neurogenic inflammation Cellular
1440 Formation of HDL-SAA HDL-SAA formation Cellular
1452 decreased DNA methylation of tyrosine hydroxylase decreased DNA methylation of tyrosine hydroxylase Cellular
1453 decreased methylation of dopamine transporter promoter decreased methylation of dopamine transporter promoter Cellular
1456 Increase, Differentiation of fibroblasts Differentiation of fibroblasts Cellular
1457 Induction, Epithelial Mesenchymal Transition EMT Cellular
1460 Increased Substance P (SP) by goblet cells SP release Cellular
1463 Inhibition of lysyl oxidase Inhibition of lysyl oxidase Cellular
1471 Increase, Uncoupling of photophosphorylation Increase, Uncoupling of photophosphorylation Cellular
1472 Decrease, ATP production Decrease, ATP production Cellular
1473 Decrease, Chlorophyll synthesis Decrease, Chlorophyll synthesis Cellular
1474 Decrease, Light harvest capacity Decrease, Light harvest capacity Cellular
1475 Decrease, Photosynthesis Decrease, Photosynthesis Cellular
1476 Decrease, Glycolysis Decrease, Glycolysis Cellular
1477 Decrease, Oxidative phosphorylation Decrease, OXPHOS Cellular
1482 Depletion, mtDNA Depletion, mtDNA Cellular
1483 Dysfunction, Mitochondria Dysfunction, Mitochondria Cellular
1488 Glutamate dyshomeostasis Glutamate dyshomeostasis Cellular
1492 Tissue resident cell activation Tissue resident cell activation Cellular
1494 Leukocyte recruitment/activation Leukocyte recruitment/activation Cellular
1496 Increased, secretion of proinflammatory mediators Increased proinflammatory mediators Cellular
1503 Histone acetylation, increase Histone acetylation, increase Cellular
1504 p21 (CDKN1A) expression, increase p21 (CDKN1A) expression, increase Cellular
1505 Cell cycle, disrupted Cell cycle, disrupted Cellular
1513 General Apoptosis General Apoptosis Cellular
1518 Photosynthesis, Decrease Photosynthesis Cellular
1519 Glycolysis Glycolysis Cellular
1520 Oxidative phosphorylation OXPHOS Cellular
1526 Increase, Opening of voltage-dependent calcium channel Increase, Opening of voltage-dependent calcium channel Cellular
1527 Increase, Cell membrane depolarization Increase, Cell membrane depolarization Cellular
1530 Decrease, Calcium currents Decrease, Calcium currents Cellular
1531 Decrease, Calcium binding to Troponin C Decrease, Calcium binding to Troponin C Cellular
1536 Disruption, Intracellular calcium mobilization Disruption, Intracellular calcium mobilization Cellular
1537 Disruption, Sarcomere assembly Disruption, Sarcomere assembly Cellular
1538 Decreased protection against oxidative stress Protection against oxidative stress, decreased Cellular
1545 Decrease in mitochondrial oxidative phosphorylation Decrease in mitochondrial oxidative phosphorylation Cellular
1546 Increased reactive oxygen species (in the mitochondria) Increased reactive oxygen species (in the mitochondria) Cellular
1547 Mitochondrial Injury Mitochondrial Injury Cellular
1555 Increase cell proliferation Increase cell proliferation Cellular
1557 Neural crest cell migration, reduced Reduced neural crest cell migration Cellular
1560 Altered differentiation Altered differentiation Cellular
1562 Decreased Na/K ATPase activity Decreased Na/K ATPase activity Cellular
1565 Suppressed AP-1 Suppressed AP-1 Cellular
1566 Suppressed NF-kB Suppressed NF-kB Cellular
1569 Impaired T cell activation Impaired T cell activation Cellular
1571 Decreased IL-1 production Decreased IL-1 production Cellular
1573 Suppressed MyD88 Suppressed MyD88 Cellular
1576 Activation, Tissue resident cells (Kuppfer cells) Activation, Tissue resident cells (Kuppfer cells) Cellular
1581 Disturbance in microtubule dynamic instability Disturbance in microtubule dynamic instability Cellular
1582 Impaired axonial transport Impaired axonial transport Cellular
1586 Airway epithelial injury Airway epithelial injury Cellular
1594 Oxidation of membrane lipids Oxidation of membrane lipids Cellular
1595 Oxidation/denatuation of membrane proteins Oxidation/denatuation of membrane proteins Cellular
1596 Oxidation of DNA Oxidation of DNA Cellular
1597 Formation of DNA photo-adducts DNA photo-adducts Cellular
1598 Formation of protein photo-adducts Protein photo-adducts Cellular
1605 Accumulation of misfolded proteins Accumulation, misfolded proteins Cellular
1606 Activation of hepatic stellate cells Activation, hepatic stellate cells Cellular
1610 Reduction, 17-OH-pregnenolone conversion in DHEA Reduction, DHEA Cellular
1611 Reduction, 17-OH-progesterone conversion in androstenedione Reduction, androstenedione Cellular
1612 Decrease, testosterone synthesis/level Decrease, testosterone level Cellular
1625 Reduction of L-Dopaquinone leads to melanin reduction melanin Cellular
1628 Reduction of L-Dopaquinone Reduction of L-Dopaquinone Cellular
1629 Reduction in melanin level Reduction in melanin level Cellular
1636 Increase, Chromosomal aberrations Increase, Chromosomal aberrations Cellular
1638 Retinoic acid (RA) synthesis decreased RA Cellular
1640 Altered, Photoreceptor patterning Altered, Photoreceptor patterning Cellular
1641 Decreased retinoic acid (RA) synthesis retinoic acid Cellular
1644 Impaired Ab production Impaired Ab production Cellular
1661 Increased Homocysteine level Homocysteine increases Cellular
1668 Frustrated phagocytosis Frustrated phagocytosis Cellular
1669 Increased, DNA damage and mutation Increased, DNA damage and mutation Cellular
1673 Alveolar collapse Alveolar collapse Cellular
1681 Disruption, Neural crest cell migration Disruption, Neural crest cell migration Cellular
1682 Disruption, Progenitor cells of second heart field Disruption, Progenitor cells of second heart field Cellular
1687 decrease, transcription of genes by AR decrease, transcription of genes by AR Cellular
1689 decrease, testosterone synthesis decrease, testosterone synthesis Cellular
1692 Reduction, Progesterone synthesis Reduction, Progesterone synthesis Cellular
1694 Reduction, progesterone uptake, decresed maturation Reduction, progesterone uptake, decresed maturation Cellular
1702 Suppression of T cell activation Suppression of T cell activation Cellular
1707 Increase, IL-23 from matured dendritic cells Increase of IL-23 Cellular
1708 Th17 cell migration and inflammation induction Th17 cell migration and inflammation induction Cellular
1711 Induction of GATA3 expression Induction of GATA3 expression Cellular
1712 Increase of Th2 cells producing IL-4 Increase of Th2 cells producing IL-4 Cellular
1713 Increase of anti-DNA antibody from autoreactive B cell Increase of autoantibody production Cellular
1716 Blockade of STAT5 phosphorylation STAT5 inhibition Cellular
1717 Suppression of STAT5 binding to cytokine gene promoters Suppression of STAT5 binding to cytokine gene promoters Cellular
1718 Suppression of IL-4 production Suppression of IL-4 production Cellular
1723 Increased exocrine secretion from pancreatic acinar cells Increased acinar cell exocrine secretion Cellular
1724 Acinar cell proliferation Acinar cell proliferation Cellular
1738 SARS-CoV-2 cell entry SARS-CoV-2 cell entry Cellular
1745 Increase,collagen synthesis Increase,collagen synthesis Cellular
1752 Increased Angiotensin II Increased AngII Cellular
1754 Porcupine-induced Wnt secretion and Wnt signaling activation Porcupine-induced Wnt secretion and Wnt signaling activation Cellular
1755 beta-catenin activation beta-catenin activation Cellular
1759 Increase, Cripto-1 expression Increase, Cripto-1 expression Cellular
1760 Inhibition, Activin signaling Inhibition, Activin signaling Cellular
1762 Urothelial cell injury/death cell injury Cellular
1770 Decrease, Mitochondrial membrane potential Decrease, MMP Cellular
1771 Decrease, Adenosine triphosphate pool Decrease, ATP pool Cellular
1775 Increase, Oocyte apoptosis Increase, Oocyte apoptosis Cellular
1776 Increase, Ovarian somatic cell apoptosis Increase, Ovarian somatic cell apoptosis Cellular
1780 Increase, Oocyte apoptosis (F3) Increase, Oocyte apoptosis (F3) Cellular
1783 Increase, Ovarian somatic cell apoptosis (F3) Increase, Ovarian somatic cell apoptosis (F3) Cellular
1787 Downregulation, ACE2 Downregulation of ACE2 Cellular
1789 Reduction, 17beta-estradiol synthesis by the undifferentiated gonad Reduction, E2 Synthesis by the undifferentiated gonad Cellular
1793 Activator protein 1 activation AP-1 activation Cellular
1794 Pin-1 activation Pin-1 activation Cellular
1795 Latent Transforming growth Factor beta expression TGFbeta expression Cellular
1800 Granulosa cell proliferation of gonadotropin-independent follicles, Reduced Reduced granulosa cell proliferation Cellular
1810 Decrease, Plasma membrane ATPase activity Decrease, ATPase activity Cellular
1812 Increase, Cytochrome c release Increase, Cyt c release Cellular
1815 Activation of ER stress ER stress Cellular
1816 Mitochondrial dysfunction Mitochondrial dysfunction Cellular
1817 Apoptotic cell death Apoptotic cell death Cellular
1818 Immune cell activation Immune cell activation Cellular
1819 IFNγ signaling IFNγ signaling Cellular
1821 Decrease, Cell proliferation Decrease, Cell proliferation Cellular
1822 Maturation of TNF/iNOS-Producing Dendritic Cells Maturation, TNF/iNOS-Producing Dendritic Cells Cellular
1823 Decrease, Lipid storage Decrease, Lipid storage Cellular
1824 Decrease, Fatty acid β-oxidation Decrease, FAO Cellular
1825 Increase, Cell death Increase, Cell death Cellular
1826 Increase, Oxygen consumption Increase, Oxygen consumption Cellular
1835 Cortisol and 11β-(OH) testosterone decreased Cortisol and 11β-(OH) testosterone decreased Cellular
1847 Increased SARS-CoV-2 production SARS-CoV-2 production Cellular
1857 Platelet-neutrophil interactions, Increased Platelet-neutrophil interactions, Increased Cellular
1858 Increased viral transcription and replication Increased viral transcription and replication Cellular
1861 Increase, D1 protein deactivation D1 protein deactivation Cellular
1862 Decrease, Photosystem II efficiency Decrease, Photosystem II efficiency Cellular
1864 Increase, Programmed cell death Increase, Programmed cell death Cellular
1869 Diminished protective oxidative stress response Diminished Protective Response to ROS Cellular
1870 Sustentacular cells, decrease Sustentacular cells, decrease Cellular
1871 olfactory sensory neurons, decrease olfacotry neurons, decrease Cellular
1874 blood brain barrier disruption BBB disruption Cellular
1876 ACE2 shedding effects on viral entry Hyunjoon Kong Cellular
1882 Disrupted meiotic initiation of fetal oogonia of the ovary Oocyte meiosis, disrupted Cellular
1889 Premature initiation of meiosis in fetal male germ cells premature meiosis, male germ cells Cellular
1890 Decrease (loss of) fetal male germ cells Germ cell loss, male Cellular
1896 Genomic instability Genomic instability Cellular
1899 formation of neutrophil extracellular traps (NETs) NETosis Cellular
1900 increased platelet surface TLR9 expression increased platelet tlr9 expression Cellular
1901 Interferon-I antiviral response, antagonized by SARS-CoV-2 IFN-I response, antagonized Cellular
1908 Cilia Beat Frequency, Decreased CBF, Decreased Cellular
1911 FOXJ1 Protein, Decreased FOXJ1 Protein, Decreased Cellular
1912 Motile Cilia Number/Length, Decreased Motile Cilia Number/Length, Decreased Cellular
1913 Endothelial cell dysfunction Endothelial cell dysfunction Cellular
1914 Platelet activation, Increased Platelet activation, Increased Cellular
1915 Neutrophil activation, Increased Neutrophil activation, Increased Cellular
1918 Increased,Myocardial apoptosis Increased,Myocardial apoptosis Cellular
1922 Increased, Reactive metabolites production Increased, metabolites Cellular
1925 Increased,Vascular smooth muscle cell activation Increased,Vascular smooth muscle cell activation Cellular
1927 Increased,Vascular endothelial cell autophagy dysfunction Increased,Vascular endothelial cell autophagy dysfunction Cellular
1933 Increased, Interleukin-6 production Increased IL-6 production Cellular
1937 ADAM17 expression induction ADAM17 induction Cellular
1942 Accumulation, Cytosolic toxic Tau oligomers Accumulation, Toxic Tau oligomers Cellular
1943 Hyperphosphorylation of Tau p-Tau Cellular
1945 Dysfunctional Autophagy Dysfunctional autophagy Cellular
1946 Impaired mechanotransduction of pericytes Altered mechanotransduction properties of pericytes Cellular
1947 Pericyte dysfunction Pericyte dysfunction Cellular
1949 Decrease, GLUT4 Decrease, GLUT4 Cellular
1951 Decrease, Glucose uptake Decrease, Glucose uptake Cellular
1958 Direct hERG channel blockage Direct hERG channel blockage Cellular
1959 Induction of hERG trafficking defects Induction of hERG trafficking defects Cellular
1967 Pyroptosis Pyroptosis Cellular
1968 Increase, Mitochondrial Dysfunction Increase, Mt Dysfunction Cellular
1972 Increased, Steroidogenic acute regulatory protein (StAR) Increased, Steroidogenic acute regulatory protein (StAR) Cellular
1973 Increased, estrogens Increased, estrogens Cellular
1974 Activation of Tumor Protein 53 Activation of TP53 Cellular
1977 Disruption of sodium channel gating kinetics Altered kinetics of sodium channel Cellular
1980 Increased microRNA expression Increase,miRNA levels Cellular
1981 Decreased SIRT1 expression Decrease,SIRT1(sirtuin 1) levels Cellular
1983 Disruption, action potential Disruption in action potential generation Cellular
1987 Decreased, Androgen and Progestin Decreased , Androgen and Progestin Cellular
1994 Increase, Ferroptosis Ferroptosis Cellular
1995 Abnormal lipid metabolism Abnormal lipid metabolism Cellular
1998 Activation, Microglia Microglia activation Cellular
2004 Increased, secretion of catecholamine Increased, secretion of catecholamine Cellular
2005 Altered neurotransmission in development neurotrasmission in development Cellular
2006 Secondary genotoxicity Secondary genotoxicity Cellular
2009 Activation of inflammation pathway Activation, inflammation pathway Cellular
2012 Fibroblast proliferation and differentiation Fibroblast proliferation and differentiation Cellular
2014 Intestinal epithelial cell apoptosis Intestinal epithelial cell apoptosis Cellular
2016 Hepatocyte cell apoptosis Hepatocyte cell apoptosis Cellular
2017 Endoplasmic reticulum stress Endoplasmic reticulum stress Cellular
2018 Insulin resistance Insulin resistance Cellular
2024 Reduced complex sphingolipids Reduced complex sphingolipids Cellular
2025 Affected folate transporter Affected folate transporter Cellular
2026 decreased folate uptake decrease folate Cellular
2033 Increased sphingolipid-1-phosphate Increased S1-P Cellular
2038 Activation of calpain signalling Activation, calpain Cellular
2040 Decrease, GLI1/2 target gene expression Decrease, GLI1/2 target gene expression Cellular
2043 Decrease, Sonic Hedgehog second messenger production Decrease, SHH second messenger production Cellular
2044 Decrease, Smoothend relocation and activation Decrease, SMO relocation Cellular
2047 Delay, Ovarian maturation Delay, Ovarian maturation Cellular
2052 Decrease, dopa decarboxylase Decrease, dopa decarboxylase Cellular
2059 Decrease, knickkopf gene Decrease, knickkopf gene Cellular
2064 Increase, Cytosolic calcium Increase, Cytosolic Ca Cellular
2065 Inhibition, Fatty acid oxidation Inhibition, Fatty acid oxidation Cellular
2067 Altered, Nitric Oxide Levels Altered, Nitric Oxide Levels Cellular
2070 Increase, Glycolysis Increase, Glycolysis Cellular
2071 Decrease, Glucose pool Decrease, Glucose pool Cellular
2072 Increase, Mitochondrial swelling Increase, Mitochondrial swelling Cellular
2078 Loss of drebrin Loss of drebrin Cellular
2079 Increased, glycolipid levels Increased glycolipid levels Cellular
2085 Pulmonary epithelial injury Pulmonary epithelial injury Cellular
2089 Altered Bone Cell Homeostasis Altered Bone Cell Homeostasis Cellular
2094 Abnormal, neuroblast migration Abnormal cell migration in brain Cellular
2100 Inhibition of rapid delayed rectifying potassium current Inhibition of rapid delayed rectifying potassium current Cellular
2102 Cytotoxicity (human trophoblast cells) Cytotoxicity (human trophoblast cells) Cellular
2103 Cellular dysfunction (human placenta trophoblast cells) Cellular dysfunction (human placenta trophoblast cells) Cellular
2106 Impaired, oligodendrocyte maturation Impaired OL maturation Cellular
2111 Decreased, neural progenitor cell adhesion to laminin NPC adhesion to laminin Cellular
2112 Disturbed, radial glia cell alignment and migration RG alignment and migration Cellular
2113 Decreased, radial glia cell density RG density Cellular
2116 Decreased, oligodendrocyte differentiation Oligodendrocyte differentiation Cellular
2117 Increase, goblet cell number Increase, goblet cell number Cellular
2120 Superoxide generation, increased Superoxide generation, increased Cellular
2127 Increased adipocyte size Increased adipocyte size Cellular
2128 Increased adipocyte numbers Increased adipocyte numbers Cellular
2130 increased lipid accumulation increased lipid accumulation Cellular
2131 Conjugation, GSH Conjugation, GSH Cellular
2132 Increased pro-inflammatory cytokine expression Increased cytokine expression Cellular
2142 Depletion, Ectoplasmic specialization (ES) Depletion of ES Cellular
2144 Impaired insulin signaling Impaired insulin signaling Cellular
2149 Increased intracelluar Iron accumulation Increased intracelluar Iron Cellular
2152 Epigenetic modification process Epigenetic modification process Cellular
2153 Expression of factors ruling proliferation, modified Expression of factors ruling proliferation, modified Cellular
2159 Influenza A virus (IAV) cell entry IAV cell entry Cellular
2162 Activation, HIF1α Activation, HIF1α Cellular
2163 Activation Sema6A Activation Sema6A Cellular
2164 Activation, Dll4-Notch pathway Activation, Dll4-Notch pathway Cellular
2165 Activation of PPAR Activation of PPAR Cellular
2166 Abnormal expression of NO Abnormal expression of NO Cellular
2167 Activation of MMP-2 MMP-9 Activation of MMP-2 MMP-9 Cellular
2168 Activation of angiopoietin like protein 4 Activation of angiopoietin like protein 4 Cellular
2169 Activation of Angiogenic cytokines Activation of Angiogenic cytokines Cellular
2171 Activated BMP/TGF-beta pathway Activated BMP/TGF-beta pathway Cellular
2172 Activated Wnt/Frizzled pathway Activated Wnt/Frizzled pathway Cellular
2173 Activated AKT/ERK/PI3K pathway Activated AKT/ERK/PI3K pathway Cellular
2174 Inhibition VEGF/VEGFR pathway Inhibition VEGF/VEGFR pathway Cellular
2175 Endothelial cell death Endothelial cell death Cellular
2176 Decreased endothelial cell proliferation Decreased endothelial cell proliferation Cellular
2177 Adhesion disfunction Adhesion disfunction Cellular
2182 Phenotype switching of vascular smooth muscle cells VSMC phenotype switching Cellular
2184 Apoptosis of vascular smooth muscle cells VSMC apoptosis Cellular
2185 Proliferation of vascular smooth muscle cells VSMC proliferation Cellular
2188 Activation, caspases Caspase activation Cellular
2189 Development-related pathway alterations Development-related pathway alterations Cellular
2190 Cardiomyocyte differentiation inhibition Cardiomyocyte differentiation inhibition Cellular
2191 Inhibition of the Wnt/β-catenin pathway Inhibition of the Wnt/β-catenin pathway Cellular
2193 Influenza A Virus (IAV) budding IAV budding Cellular
2195 Increase, CNS Neural cell death Increase, CNS Neural cell death Cellular
2203 Decreased proliferation of cortical neural progenitor cells Decreased proliferation of cortical NPCs Cellular
2207 inhibition, EKR1/2 signaling pathway inhibition, EKR1/2 signaling pathway Cellular
78 Reduction, Cumulative fecundity and spawning Reduction, Cumulative fecundity and spawning Individual
152 Suppression, Inflammatory cytokines Suppression, Inflammatory cytokines Individual
168 Decreased, Lymphocytes Decreased, Lymphocytes Individual
253 N/A, Reproductive failure N/A, Reproductive failure Individual
270 Induction, Sustained Hepatotoxicity Induction, Sustained Hepatotoxicity Individual
312 N/A, Allergic contact dermatitis on challenge N/A, Allergic contact dermatitis on challenge Individual
321 N/A, Cyanosis occurs N/A, Cyanosis occurs Individual
323 Increased, Disease susceptibility Increased, Disease susceptibility Individual
328 Decrease, Fecundity Decrease, Fecundity Individual
330 Decrease, Fertility Decrease, Fertility Individual
334 Promotion, Hepatocelluar carcinoma Promotion, Hepatocelluar carcinoma Individual
336 Increase, Heritable mutations in offspring Increase, Heritable mutations in offspring Individual
337 N/A, Impairment of reproductive capacity N/A, Impairment of reproductive capacity Individual
339 Altered, Larval development Altered, Larval development Individual
341 Impairment, Learning and memory Impairment, Learning and memory Individual
347 Formation, Liver tumor Formation, Liver tumor Individual
350 Increase, Mortality Increase, Mortality Individual
356 Increased, Oxidative damage Increased, Oxidative damage Individual
357 Cholestasis, Pathology Cholestasis, Pathology Individual
363 Altered, Reproductive behaviour Altered, Reproductive behaviour Individual
364 Impaired development of, Reproductive organs Impaired development of, Reproductive organs Individual
369 Uroporphyria Uroporphyria Individual
378 Tumorigenesis, Hepatocellular carcinoma Tumorigenesis, Hepatocellular carcinoma Individual
402 Cognitive Function, Decreased Cognitive Function, Decreased Individual
403 Suppression, Immune system Suppression, Immune system Individual
405 irregularities, ovarian cycle irregularities, ovarian cycle Individual
406 impaired, Fertility impaired, Fertility Individual
422 Increased, nephropathy Increased, nephropathy Individual
505 Decreased sperm quantity / quality in the adult, Decreased fertility Decreased sperm quantity / quality in the adult, Decreased fertility Individual
520 Decreased sperm quantity or quality in the adult, Decreased fertility Decreased sperm quantity or quality in the adult, Decreased fertility Individual
527 Decreased, Decreased fecundity Decreased, Decreased fecundity Individual
532 Delayed, Ovulation Delayed, Ovulation Individual
543 Decreased fertility in the adult, Decreased sperm quantity and/or quality in the adult testis Decreased fertility in the adult, Decreased sperm quantity and/or quality in the adult test Individual
560 Abnormal, Foraging activity and behavior Abnormal, Foraging activity and behavior Individual
571 Accelerated, Aging Accelerated, Aging Individual
573 Increase, Energetic demands and therefore metabolic stress Increase, Energetic demands and therefore metabolic stress Individual
574 Increased, Appetite and hunger Increased, Appetite and hunger Individual
576 Increased, Viral susceptibility Increased, Viral susceptibility Individual
577 impaired, Development impaired, Development Individual
583 impaired, Thoracic shivering impaired, Thoracic shivering Individual
586 Reduced, swimming speed Reduced, swimming speed Individual
587 Reduced, feeding 1 Reduced, feeding 1 Individual
591 Increased, amputations Increased, amputations Individual
613 Occurrence, Epileptic seizure Occurrence, Epileptic seizure Individual
622 Increased, locomotion Increased, locomotion Individual
624 Increased, foot detachment Increased, foot detachment Individual
627 Decreased, anxiety Decreased, anxiety Individual
629 Decreased, sheltering Decreased, sheltering Individual
634 N/A, sedation N/A, sedation Individual
635 Decreased, locomotion Decreased, locomotion Individual
637 impaired, Learning and memory impaired, Learning and memory Individual
671 Reduced, Prostaglandin F2alpha concentration, plasma Reduced, Prostaglandin F2alpha concentration, plasma Individual
673 Reduced, Spawning behavior Reduced, Spawning behavior Individual
674 Reduced, Ability to attract spawning mates Reduced, Ability to attract spawning mates Individual
675 Reduced, Reproductive Success Reduced, Reproductive Success Individual
678 Reduced, Pheromone release Reduced, Pheromone release Individual
728 Increase, Aneuploid offspring Increase, Aneuploid offspring Individual
808 Decreased, Testosterone Decreased, Testosterone Individual
809 malformed, Male reproductive tract malformed, Male reproductive tract Individual
864 Decreased, Body Weight Decreased, Body Weight Individual
896 Parkinsonian motor deficits Parkinsonian motor deficits Individual
947 Increase, Early Life Stage Mortality Increase, Early Life Stage Mortality Individual
952 Hypertension Hypertension Individual
971 Ovulation of oocytes Reduced, Delayed, or Blocked, Decrease or delay in LH surge required for ovulation Reduced Ovulation of oocytes Individual
972 Decreased fertility, Reduced number of oocytes ovulated Decreased fertility, Reduced number of oocytes ovulated Individual
984 Impairment, T-cell dependent antibody response Impairment, T-cell dependent antibody response Individual
985 Relief, Relief of atopic dermatitis Relief, Relief of atopic dermatitis Individual
986 Impairment of TDAR Impairment of TDAR Individual
990 Increase, Incomplete ecdysis Increase, Incomplete ecdysis Individual
1005 Reduced, Swimming performance Reduced, Swimming performance Individual
1016 Inhibition, Feeding Inhibition, Feeding Individual
1074 interruption, Ovulation interruption, Ovulation Individual
1075 prolonged, estrus prolonged, estrus Individual
1080 Increased, latency period Increased, latency period Individual
1109 Increased, Deformed Wing Virus levels Increased, Deformed Wing Virus levels Individual
1110 Increased, Energetic demands and therefore metabolic stress Increased, Energetic demands and therefore metabolic stress Individual
1140 Delayed, Sexual maturity Delayed, Sexual maturity Individual
1141 Decreased, Reproductive Success Decreased, Reproductive Success Individual
1143 Depletion, energy reserves Depletion, energy reserves Individual
1146 premature, Spawning premature, Spawning Individual
1147 increased or inappropriate, mantel display increased or inappropriate, mantel display Individual
1151 Osteoporosis and vascular calcification, Bone deterioration Osteoporosis and vascular calcification, Bone deterioration Individual
1160 Increased, mantel display Increased, mantel display Individual
1163 Increased, Reproductive Success Increased, Reproductive Success Individual
1167 induced, parturition induced, parturition Individual
1193 N/A, Breast Cancer N/A, Breast Cancer Individual
1224 Non-neuronal production of TNF, Epithelial irritation Non-neuronal production of TNF, Epithelial irritation Individual
1237 Sensitization, Immune system Sensitization, Immune system Individual
1250 Decrease, Lung function Decreased lung function Individual
1254 Infant leukaemia IFL Individual
1255 induced spawning induced spawning Individual
1257 Induced parturition Induced parturition Individual
1277 Reproductive failure Reproductive failure Individual
1327 Decreased, seizure Decreased, seizure Individual
1331 Inhibit, agitation Inhibit, agitation Individual
1332 Inhibit, depression Inhibit, depression Individual
1333 Increase, mental stress Increase, mental stress Individual
1343 Increase, hypertension Increase, hypertension Individual
1344 Increased, seizure Increased, seizure Individual
1346 Increased, depression Increased, depression Individual
1348 Increase, seizure Increase, seizure Individual
1363 Increased, epilepsy Increased, epilepsy Individual
1389 Locomotor activity, decreased Locomotor activity, decreased Individual
1390 Sexual behavior, decreased Sexual behavior, decreased Individual
1428 Analgesia Analgesia Individual
1432 Anti-depressant Activity Anti-depressant Activity Individual
1443 Atherosclerosis Atherosclerosis Individual
1447 obesity obesity Individual
1451 decreased reward decreased reward Individual
1454 chronic high fat diet chronic high fat diet Individual
1467 Growth, reduction Growth, reduction Individual
1470 inherited mutations in offspring increase in inherited mutations Individual
1521 Decrease, Growth Decrease, Growth Individual
1524 Increase, Premature molting Increase, Premature molting Individual
1534 Decrease, Blood pressure Decrease, Blood pressure Individual
1564 Chemical induced Fanconi syndrome Chemical induced Fanconi syndrome Individual
1583 Sensory axonal peripheral neuropathy Sensory axonal peripheral neuropathy Individual
1588 Bronchiolitis obliterans Bronchiolitis obliterans Individual
1618 Reduction, egg production and spawning Reduction, egg production and spawning Individual
1631 Reduction fo Pigmentation pattern Reduction fo Pigmentation pattern Individual
1664 Induce Neuronal dysfunctions Neuronal dysfunctions induction Individual
1667 Impaired,anterior-posterior axis development anterior-posterior axis development Individual
1679 Acute inhalation toxicity Acute inhalation toxicity Individual
1685 Anomalies, Congenital cardiac conotruncal Anomalies, Congenital cardiac conotruncal Individual
1696 Decrease of egg production and cummulative fecundity Decrease of egg production and cummulative fecundity Individual
1705 Impaired coordination and movement Impaired coordination and movement Individual
1709 Psoriatic skin disease Skin disease Individual
1714 Exacerbation of systemic lupus erythematosus (SLE) Exacerbation of SLE Individual
1719 Impairment of T-cell dependent antibody response Impairment, TDAR Individual
1751 Decreased mortality Decreased mortality Individual
1757 Reduce, Sperm count Reduce, Sperm count Individual
1781 Decrease, Fecundity (F3) Decrease, Fecundity (F3) Individual
1786 Nipple retention (NR), increased nipple retention, increased Individual
1788 Status epilepticus Status epilepticus Individual
1833 Impaired lung function Impaired lung function Individual
1843 Multi Organ Failure involving Acute Respiratory Distress Syndrome ARDS and MODS Individual
1844 systemic inflammatory response syndrome SIRS Individual
1846 Thrombosis and Disseminated Intravascular Coagulation Thrombosis and DIC Individual
1863 Decrease, Reproduction Decrease, Reproduction Individual
1893 increase, Preeclampsia increase, Preeclampsia Individual
1894 chronic low grade systemic inflammation low grade inflammation Individual
1909 Mucociliary Clearance, Decreased MCC, Decreased Individual
1932 Gastrointestinal disorders GI disorders Individual
1939 Viral infection and host-to-host transmission, proliferated Viral infection, proliferated Individual
1941 Memory Loss Memory Loss Individual
1953 Gestational diabetes mellitus GDM Individual
1955 Acute Myeloid Leukemia AML Individual
1964 Sudden cardiac death Sudden cardiac death Individual
1966 Decrease, Asexual reproduction Decrease, Asexual reproduction Individual
1978 Increase risk, microcephaly Microcephaly Individual
2008 Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease Individual
2019 Non-alcoholic fatty liver disease Non-alcoholic fatty liver disease Individual
2032 Viable offspring, decreased Viable offspring, decreased Individual
2042 Orofacial clefting OFC Individual
2048 Increase, Body volume of female adults Increase, Body volume of female adults Individual
2049 Increase, sex ratio (F/M) Increase, sex ratio (F/M) Individual
2050 Increase, developmental abnormalities Increase, developmental abnormalities Individual
2053 Increase, Defects in tanning of new cuticle Increase, Defects in tanning of new cuticle Individual
2054 Increase, impairment of cuticle sclerotization Increase, impairment of cuticle sclerotization Individual
2055 Increase, pigmentation Increase, pigmentation Individual
2056 Increase, delay in oviposition Increase, delay in oviposition Individual
2057 Decrease, hatching of egg Decrease, hatching of egg Individual
2077 Increase, pulmonate breathing behavioral change leading to possible reduced feeding opportunity Individual
2087 Increased incidence of respiratory disease Increased incidence of respiratory disease Individual
2088 Dysfunction of respiratory system Respiratory dysfunction Individual
2095 Periventricular heterotopia formation Heterotopia formation Individual
2119 Insulin resistance, increased Insulin resistance, increased Individual
2129 Metabolically unhealthy Obesity Metabolically unhealthy Obesity Individual
2135 Prostate cancer Prostate cancer Individual
2140 Decreased spawning and cumulative fecundity, decreased gonadosomatic index Decreased spawning and cumulative fecundity, decreased GSI Individual
2147 Decreased, Viable Offspring Decreased, Viable Offspring Individual
2150 Neurological disorder Neurological disorder Individual
2161 Increase, Vascular disrupting effects Increase, Vascular disrupting effects Individual
2194 Influenza A Virus (IAV) shedding and transmission infection proliferation Individual
2209 autism-like behavior autism-like behavior Individual
9 Activation, 5HT2c Activation, 5HT2c Molecular
17 Altered gene expression, AHR nuclear translocator (ARNT)-dependent pathway Altered expression of AHR/ARNT pathway-dependent genes Molecular
18 Activation, AhR Activation, AhR Molecular
25 Agonism, Androgen receptor Agonism, Androgen receptor Molecular
26 Antagonism, Androgen receptor Antagonism, Androgen receptor Molecular
27 N/A, Androgen receptor, Antagonism N/A, Androgen receptor, Antagonism Molecular
28 Reduction, Angiogenesis Reduction, Angiogenesis Molecular
36 Inhibition, Aromatase Inhibition, Aromatase Molecular
41 Inhibition, Bile Salt Export Pump (ABCB11) Inhibition, Bile Salt Export Pump (ABCB11) Molecular
51 Inhibition, Ca++ ATPase Inhibition, Ca++ ATPase Molecular
54 Up Regulation, CD36 Up Regulation, CD36 Molecular
66 Activation, ChREBP Activation, ChREBP Molecular
75 N/A, Covalent binding to protein, possibly lysine residue N/A, Covalent binding to protein, possibly lysine residue Molecular
79 Inhibition, Cyclooxygenase activity Inhibition, Cyclooxygenase activity Molecular
80 Up Regulation, CYP1A1 Up Regulation, CYP1A1 Molecular
84 Up Regulation, CYP1B1 Up Regulation, CYP1B1 Molecular
97 Alkylation, DNA Alkylation, DNA Molecular
103 Increase, Ecdysone receptor agonism Increase, EcR agonism Molecular
105 Inhibition, Mitochondrial Electron Transport Chain Complexes Inhibition, ETC complexes of the respiratory chain Molecular
111 Agonism, Estrogen receptor Agonism, Estrogen receptor Molecular
112 Antagonism, Estrogen receptor Antagonism, Estrogen receptor Molecular
116 Activation, FAS Activation, FAS Molecular
122 Activation, Glucocorticoid Receptor Activation, Glucocorticoid Receptor Molecular
151 Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways Molecular
167 Activation, LXR Activation, LXR Molecular
179 Decreased, Mitochondrial fatty acid beta-oxidation Decreased, Mitochondrial fatty acid beta-oxidation Molecular
185 Increase, Mutations Increase, Mutations Molecular
195 Inhibition, NMDARs Inhibition, NMDARs Molecular
201 Binding of antagonist, NMDA receptors Binding of antagonist, NMDA receptors Molecular
202 Inhibition, Nuclear factor kappa B (NF-kB) Inhibition, Nuclear factor kappa B (NF-kB) Molecular
209 Peptide Oxidation Peptide Oxidation Molecular
211 Propagation, Oxidative stress Propagation, Oxidative stress Molecular
213 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III) N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin Molecular
227 Activation, PPARα Activation, PPARα Molecular
228 peroxisome proliferator activated receptor promoter demethylation demethylation, PPARg promoter Molecular
231 Decreased, PPAR-alpha activation Decreased, PPAR-alpha activation Molecular
232 Decreased, PPAR-beta activation Decreased, PPAR-beta activation Molecular
233 Decreased, PPAR-gamma activation Decreased, PPAR-gamma activation Molecular
234 Activation, PPARα & PPARγ Activation, PPARα & PPARγ Molecular
239 Activation, Pregnane-X receptor, NR1l2 Activation, Pregnane-X receptor, NR1l2 Molecular
244 Alkylation, Protein Alkylation, Protein Molecular
245 Activation, PXR/SXR Activation, PXR/SXR Molecular
257 Increase, Reactive Oxygen Species production Increase, ROS production Molecular
258 Activation, SCD-1 Activation, SCD-1 Molecular
261 Binding, SH-/selen-proteins Binding, SH-/selen-proteins Molecular
264 Activation, SREBP-1c Activation, SREBP-1c Molecular
279 Thyroperoxidase, Inhibition Thyroperoxidase, Inhibition Molecular
294 N/A, Unknown N/A, Unknown Molecular
295 Induction, Upregulation of glucuronyltransferase activity Induction, Upregulation of glucuronyltransferase activity Molecular
298 Insufficiency, Vascular Insufficiency, Vascular Molecular
305 Inhibition, VegfR2 Inhibition, VegfR2 Molecular
373 Formation, Pro-mutagenic DNA Adducts Formation, Pro-mutagenic DNA Adducts Molecular
380 Activation, Pre-MIE: Metabolism of AFB1 Activation, Pre-MIE: Metabolism of AFB1 Molecular
381 Reduced levels of BDNF BDNF, Reduced Molecular
383 Reduced, Presynaptic release of glutamate Reduced, Presynaptic release of glutamate Molecular
387 Binding of agonist, NMDARs Binding of agonist, NMDARs Molecular
396 Covalent Binding, Protein Covalent Binding, Protein Molecular
409 Metabolism of AFB1, Production of Reactive Electrophiles Metabolism of AFB1, Production of Reactive Electrophiles Molecular
424 Inhibition, Na+/I- symporter (NIS) Inhibition, Na+/I- symporter (NIS) Molecular
451 Inhibition, Mitochondrial fatty acid beta-oxidation Inhibition, Mitochondrial fatty acid beta-oxidation Molecular
456 Suppression, Constitutive androstane receptor, NR1l3 Suppression, Constitutive androstane receptor, NR1l3 Molecular
457 Activation, SREBF1 Activation, SREBF1 Molecular
461 Suppression, HNF4alpha Suppression, HNF4alpha Molecular
462 Up Regulation, SCD-1 Up Regulation, SCD-1 Molecular
463 Up Regulation, FAS Up Regulation, FAS Molecular
466 Up Regulation, LDLR (low density lipoprotein receptor) Up Regulation, LDLR (low density lipoprotein receptor) Molecular
468 Inhibition, PPAR alpha Inhibition, PPAR alpha Molecular
470 Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1) Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1) Molecular
471 Inhibition, FoxA2 Inhibition, FoxA2 Molecular
472 Down Regulation, CPT1A Down Regulation, CPT1A Molecular
474 Down Regulation, HMGCS2 Down Regulation, HMGCS2 Molecular
478 Activation, NRF2 Activation, NRF2 Molecular
479 Activation, NR1H4 Activation, NR1H4 Molecular
480 Activation, SHP Activation, SHP Molecular
482 Decreased, DHB4/HSD17B4 Decreased, DHB4/HSD17B4 Molecular
483 Activation, LXR alpha Activation, LXR alpha Molecular
484 Activation, AKT2 Activation, AKT2 Molecular
493 Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts Molecular
494 Glucocorticoid Receptor Agonist, Activation GR Agonist, Activation Molecular
526 Inhibition, Inhibition of Dopamine-beta-hydroxylase Inhibition, Inhibition of Dopamine-beta-hydroxylase Molecular
529 Decreased, GnRH cfos activity Decreased, GnRH cfos activity Molecular
559 Activation, Nicotinic acetylcholine receptor Activation, Nicotinic acetylcholine receptor Molecular
578 Decreased, Glucose oxidase enzyme activity Decreased, Glucose oxidase enzyme activity Molecular
579 Decreased, Hydrogen peroxide production Decreased, Hydrogen peroxide production Molecular
584 Inhibition, sodium channel Inhibition, sodium channel Molecular
593 Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel Molecular
598 modulation, sodium channel modulation, sodium channel Molecular
600 Overactivation, Neuronotransmitter release Overactivation, Neuronotransmitter release Molecular
619 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) Molecular
620 Increased, serotonin (5-HT) 1 1 Increased, serotonin (5-HT) 1 Molecular
638 Antagonism, Histamine Receptor (H2) Antagonism, Histamine Receptor (H2) Molecular
640 Decreased steroidogenesis, Proteomic alterations in the adult Leydig cell Decreased steroidogenesis, Proteomic alterations in the adult Leydig cell Molecular
642 Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol Molecular
643 Decreased Cholesterol, Decreased Uptake of Lipoproteins Decreased Cholesterol, Decreased Uptake of Lipoproteins Molecular
644 Decreased Cholesterol, Decreased Transport of Cholesterol to the Inner Mitochondrial Membrane Decreased Cholesterol, Decreased Transport of Cholesterol to the Inner Mitochondrial Membra Molecular
650 Stimulation of adult Leydig cells via the Adrenal Corticosterone, Increased Glucocorticoid Stimulation of adult Leydig cells via the Adrenal Corticosterone, Increased Glucocorticoid Molecular
661 Decreased testosterone by the fetal Leydig cells, Alterations in the fetal testis proteome Decreased testosterone by the fetal Leydig cells, Alterations in the fetal testis proteome Molecular
662 Decreased testosterone by the fetal Leydig cells, Hypermethylation in the fetal testis Decreased testosterone by the fetal Leydig cells, Hypermethylation in the fetal testis Molecular
663 Desensitization, Nicotinic acetylcholine receptor Desensitization, Nicotinic acetylcholine receptor Molecular
667 Binding at picrotoxin site, iGABAR chloride channel Binding at picrotoxin site, iGABAR chloride channel Molecular
695 Upregulated, Spindle assembly checkpoint protein Mad2-oocyte Upregulated, Spindle assembly checkpoint protein Mad2-oocyte Molecular
714 Increased, Binding of chemicals to 2u (serum) Increased, Binding of chemicals to 2u (serum) Molecular
715 Activation, Constitutive androstane receptor Activation, Constitutive androstane receptor Molecular
718 Binding, Tubulin Binding, Tubulin Molecular
720 Disruption, Microtubule dynamics Disruption, Microtubule dynamics Molecular
726 Increased, Induction of pyruvate dehydrogenase (PDH) Increased, Induction of pyruvate dehydrogenase (PDH) Molecular
742 Decreased, Androgen receptor activity Decreased, Androgen receptor activity Molecular
743 Decreased, Testosterone binding to androgen receptor (hypothalamus) Decreased, Testosterone binding to androgen receptor (hypothalamus) Molecular
748 Increased, Estrogen receptor (ER) activity Increased, Estrogen receptor (ER) activity Molecular
760 Activation, Glutamate-gated chloride channel Activation, Glutamate-gated chloride channel Molecular
762 Activation, ionotropic GABA Receptor chloride channel Activation, ionotropic GABA Receptor chloride channel Molecular
766 Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme Molecular
785 Activation, Androgen receptor Activation, Androgen receptor Molecular
801 modulation, Unknown modulation, Unknown Molecular
828 Inhibition, Phospholipase A Inhibition, Phospholipase A Molecular
845 Inhibition, UROD Inhibition, UROD Molecular
849 Inhibition, Antgonism of NE receptor Inhibition, Antgonism of NE receptor Molecular
850 Induction, CYP1A2/CYP1A5 Induction, CYP1A2/CYP1A5 Molecular
857 Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain Molecular
858 Decreased, PPARalpha transactivation of gene expression Decreased, PPARalpha transactivation of gene expression Molecular
859 Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids Molecular
860 Decreased, Mitochondrial Fatty Acid Beta Oxidation Decreased, Mitochondrial Fatty Acid Beta Oxidation Molecular
875 Binding of agonist, Ionotropic glutamate receptors Binding of agonist, Ionotropic glutamate receptors Molecular
876 Increase, Mutations in Critical Genes Increase, Mutations in Critical Genes Molecular
877 Inhibition, organic anion transporter 1 (OAT1) Inhibition, organic anion transporter 1 (OAT1) Molecular
878 Inhibition, SREBP1c Inhibition, SREBP1c Molecular
888 Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) Molecular
924 Activation, Sp1 Activation, Sp1 Molecular
926 Oxidation, Glutathione (To be considered with MIE) Oxidation, Glutathione Molecular
927 KE1 : S-Glutathionylation, eNOS S-Glutathionylation, eNOS Molecular
941 Activation, EGFR Activation, EGFR Molecular
944 dimerization, AHR/ARNT dimerization, AHR/ARNT Molecular
945 reduced dimerization, ARNT/HIF1-alpha reduced dimerization, ARNT/HIF1-alpha Molecular
957 Binding, Transthyretin in serum Binding, Transthyretin in serum Molecular
958 Displacement, Serum thyroxine (T4) from transthyretin Displacement, Serum thyroxine (T4) from transthyretin Molecular
964 Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle between diestrus 2 and proestrus inhibits aromatase conversion of testosterone to estradiol Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle b Molecular
976 Formation, The binding of FK506 with FKBP12 Formation, The binding of FK506 with FKBP12 Molecular
978 Activation, Suppression of NFAT activation and hindrance of nuclear localization Activation, Suppression of NFAT activation and hindrance of nuclear localization Molecular
979 Interference, nuclear localization of NFAT Interference, nuclear localization of NFAT Molecular
980 Inhibition, Calcineurin Activity Inhibition, Calcineurin Activity Molecular
987 Metaplasia of goblet cells Metaplasia of goblet cells Molecular
998 Binding of antagonist, PPAR alpha Binding of antagonist, PPAR alpha Molecular
1000 stabilization, PPAR alpha co-repressor stabilization, PPAR alpha co-repressor Molecular
1001 Increased, Developmental Defects Increased, Developmental Defects Molecular
1002 Inhibition, Deiodinase 2 Inhibition, Deiodinase 2 Molecular
1009 Inhibition, Deiodinase 1 Inhibition, Deiodinase 1 Molecular
1018 Activation, Glutamate-gated chloride channels Activation, Glutamate-gated chloride channels Molecular
1028 Activation of specific nuclear receptors, PPAR-gamma activation Activation of specific nuclear receptors, PPAR-gamma activation Molecular
1038 Activation, beta-2 adrenergic receptor Activation, beta-2 adrenergic receptor Molecular
1039 Increased activity, beta-2 adrenergic receptor Increased activity, beta-2 adrenergic receptor Molecular
1046 Suppression, Estrogen receptor (ER) activity Suppression, Estrogen receptor (ER) activity Molecular
1057 Increased, PPAR-alpha activation Increased, PPAR-alpha activation Molecular
1064 prepubertal increase, Estrogen receptor (ER) activity prepubertal increase, Estrogen receptor (ER) activity Molecular
1065 Activation, estrogen receptor alpha Activation, estrogen receptor alpha Molecular
1088 Increased, Oxidative Stress Increased, Oxidative Stress Molecular
1103 Inhibition, Cyclooxygenase 1 activity Inhibition, Cyclooxygenase 1 activity Molecular
1114 Unknown, MIE Unknown, MIE Molecular
1131 Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo Molecular
1134 Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle Molecular
1138 Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP Molecular
1152 Inhibition, Iodotyrosine deiodinase (IYD) Inhibition, Iodotyrosine deiodinase (IYD) Molecular
1153 Inhibition, Deiodinase 3 Inhibition, Deiodinase 3 Molecular
1155 Inhibition, Pendrin Inhibition, Pendrin Molecular
1156 Inhibition, Dual oxidase Inhibition, Dual oxidase Molecular
1157 Activation, Hepatic nuclear receptor(s) Activation, Hepatic nuclear receptor(s) Molecular
1169 Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcin Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment Molecular
1173 Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids Molecular
1174 Activation, NADPH Oxidase Activation, NADPH Oxidase Molecular
1181 Activation, Estrogen receptor Activation, Estrogen receptor Molecular
1187 Increased, ER binding to DNA (classical pathway) Increased, ER binding to DNA (classical pathway) Molecular
1188 Increased, ER binding to T.F. to DNA (non-classical pathway) Increased, ER binding to T.F. to DNA (non-classical pathway) Molecular
1194 Increase, DNA damage Increase, DNA Damage Molecular
1201 Binding, Immunophilins Binding, Immunophilins Molecular
1205 Activation, Juvenile hormone receptor Activation, Juvenile hormone receptor Molecular
1206 Induction, Doublesex1 gene Induction, Doublesex1 gene Molecular
1215 TRPA1 activation, TRPA1 Receptor TRPA1 activation, TRPA1 Receptor Molecular
1230 TRPV1 activation, TRPV1 TRPV1 activation, TRPV1 Molecular
1238 Activation of oxidative stress pathway Oxidation Molecular
1239 Altered, Gene Expression Altered, Gene Expression Molecular
1252 Binding to (interferes with) topoisomerase II enzyme Binding, topoisomerase II Molecular
1260 Direct mitochondrial inhibition Direct mitochondrial inhibition Molecular
1261 Mitochondrial impairment Mitochondrial impairment Molecular
1264 Increase, Nuclear receptor E75b gene expression Increase, E75b expression Molecular
1265 Increase, Fushi tarazu factor-1 gene expression Increase, Ftz-f1 expression Molecular
1269 Increase, COX-2 expression Increase, COX-2 expression Molecular
1270 Inactivation of PPARγ Inactivation of PPARγ Molecular
1278 ROS formation ROS formation Molecular
1296 Increase, insulin Increase, insulin Molecular
1297 Activation, insulin receptor Activation, insulin receptor Molecular
1298 Activation, mTORC2 Activation, mTORC2 Molecular
1299 Activation, AKT Activation, AKT Molecular
1300 Activation, mTORC1 Activation, mTORC1 Molecular
1301 Activation, SREBP-1 Activation, SREBP-1 Molecular
1302 Activation, L-FABP Activation, L-FABP Molecular
1303 Activation, HSD17B4 Activation, HSD17B4 Molecular
1304 Activation, FXR Activation, FXR Molecular
1306 Increased, lipogenesis Increased, lipogenesis Molecular
1307 Inhibition, LXR Inhibition, LXR Molecular
1308 Inhibition, LRH-1 Inhibition, LRH-1 Molecular
1309 Activation, aPKC Activation, aPKC Molecular
1310 Activation, PI3K Activation, PI3K Molecular
1313 Decrease, cytosolic fatty acid Decrease, cytosolic fatty acid Molecular
1314 Activation, LRH-1 Activation, LRH-1 Molecular
1315 Increase, Selective Serotonin Reuptake Inhibitors (SSRIs) Increase, SSRIs Molecular
1316 Inhibit, serotonin transporter activity Inhibit, serotonin transporter activity Molecular
1317 Decreased, serotonin transporter activity Decreased, serotonin transporter activity Molecular
1318 Decreased, extracellular sodium (Na+) Decreased, extracellular Na+ Molecular
1319 Decreased, extracellular chloride (Cl-) Decreased, extracellular chloride (Cl-) Molecular
1320 Increased, extracellular serotonin Increased, extracellular serotonin Molecular
1321 Increased, intracellular sodium (Na+) Increased, intracellular sodium (Na+) Molecular
1322 Increased, intracellular chloride (Cl-) Increased, intracellular chloride (Cl-) Molecular
1323 Decreased, intracellular serotonin Decreased, intracellular serotonin Molecular
1324 Decreased, packaged serotonin Decreased, packaged serotonin Molecular
1325 Decreased, synaptic release Decreased, synaptic release Molecular
1326 Increased, 5-HT3 (5-hydroxytryptamine) Increased, 5-HT3 Molecular
1328 Inactivated, 5-HTR (serotonin receptors) Inactivated, 5-HTR Molecular
1329 Reduce expression, BDNF (Brain-derived neurotrophic factor) Reduce expression, BDNF Molecular
1330 Decreased, neuroplasticity Decreased, neuroplasticity Molecular
1334 Increase, cortisone Increase, cortisone Molecular
1335 Reduced, BDNF (Brain-derived neurotrophic factor) Reduced, BDNF Molecular
1336 Activation, 5-HT2A (Serotonin 2A) Activation, 5-HT2A Molecular
1337 Activate, PLC (Phospholipase C) Activate, PLC Molecular
1338 Increase, inositol triphosphate Increase, inositol triphosphate Molecular
1340 Activate, calmodulin Activate, calmodulin Molecular
1341 Increase, myosin light chain phosphorylation Increase, myosin light chain phosphorylation Molecular
1342 Increase, vascular smooth muscle contraction Increase, vascular smooth muscle contraction Molecular
1345 Increased, agitation Increased, agitation Molecular
1347 Decreased, extracellular serotonin Decreased, extracellular serotonin Molecular
1349 Activated, presynaptic neuron 1 Activated, presynaptic neuron 1 Molecular
1350 Increased, glutamate Increased, glutamate Molecular
1351 Activated, NMDA receptor Activated, NMDA receptor Molecular
1352 Activated, voltage-gated sodium channel Activated, voltage-gated sodium channel Molecular
1353 Binding to voltage-gated sodium channel Binding to VGSC Molecular
1354 Treat, carbamazepine Treat, carbamazepine Molecular
1356 Inactive, membrane depolarization Inactive, membrane depolarization Molecular
1357 Increased, RDX dose Increased, RDX dose Molecular
1358 Repress, GABA-A receptor Repress, GABA-A receptor Molecular
1359 Activate, GABA-A receptor Activate, GABA-A receptor Molecular
1360 Activate, presynaptic neuron 2 Activate, presynaptic neuron 2 Molecular
1361 Increase, GABA Increase, GABA Molecular
1362 Increased, hippocampal hyperdepolarization Increased, hippocampal hyperdepolarization Molecular
1364 Increase, Reactive oxygen species Increase, ROS Molecular
1368 Inhibition, PTGS-1 (Prostaglandin-endoperoxide synthase 1) Inhibition, PTGS-1 Molecular
1369 Activation, PTGS-1 (Prostaglandin-endoperoxide synthase 1) Activation, PTGS-1 Molecular
1370 Activation, PTGS-2 (Prostaglandin-endoperoxide synthase 2) Activation, PTGS-2 Molecular
1371 Inhibition, PTGS-2 (Prostaglandin-endoperoxide synthase 2) Inhibition, PTGS-2 (Prostaglandin-endoperoxide synthase 2) Molecular
1372 Increase, bicarbonate Increase, bicarbonate Molecular
1373 Increase, mucous Increase, mucous Molecular
1381 Increase, surfactant Increase, surfactant Molecular
1382 Decrease, surfactant Decrease, surfactant Molecular
1383 Activate, phospholipase Activate, phospholipase Molecular
1384 Increase, ammonium (NH4+) Increase, ammonium (NH4+) Molecular
1386 CYP7B activity, inhibition CYP7B activity, inhibition Molecular
1391 Activation of Cyp2E1 Activation of Cyp2E1 Molecular
1392 Oxidative Stress Oxidative Stress Molecular
1396 Increased, glucocorticoid receptor activity Increased, glucocorticoid receptor activity Molecular
1402 Reduced, PTGS1 function Reduced, PTGS1 function Molecular
1415 Reduced, GABA-A receptor activation Reduced, GABA-A receptor activation Molecular
1417 NFE2/Nrf2 repression NFE2/Nrf2 repression Molecular
1419 Reduced, FXR activity Reduced, FXR activity Molecular
1420 Reduced, SHP activity Reduced, SHP activity Molecular
1421 Activated, LXR Activated, LXR Molecular
1422 Reduced, PPARalpha Reduced, PPARalpha Molecular
1423 Reduced, HSD17B4 activity Reduced, HSD17B4 activity Molecular
1424 Reduced, fatty acid beta oxidation Reduced, fatty acid beta oxidation Molecular
1425 Mu Opioid Receptor Agonism Mu Opioid Receptor Agonism Molecular
1431 Serotonin 1A Receptor Agonism Serotonin 1A Receptor Agonism Molecular
1437 Sensing of the stressor by pulmonary cells Sensing of the stressor Molecular
1445 Increased, Lipid peroxidation Increased, LPO Molecular
1446 Decrease, Coupling of oxidative phosphorylation Decrease, Coupling of OXPHOS Molecular
1448 activation of CCAAT/enhancer-binding protein alpha activation of CEBPA Molecular
1450 decreased dopamine decreased dopamine Molecular
1455 Incudtion, Sustained inflammatory cytokine release Sustained inflammatory cytokine release Molecular
1459 Induction, Cell damage sensing Cell damage sensing Molecular
1461 Increase, DNA double-strand breaks Increase, DSB Molecular
1462 Thiol group of chemicals interact with sulfuhydryl groups of proteins to form thiol adducts Thiol protein adducts Molecular
1468 Activation, Latent Transforming Growth Factor Beta 1 TGFbeta1 activation Molecular
1469 Activation, Transforming Growth Factor beta pathway TGFbeta pathway activation Molecular
1481 Inhibition of mitochondrial DNA polymerase gamma (Pol gamma) Inhibition, mitochondrial DNA polymerase gamma (Pol gamma) Molecular
1484 Receptor mediated endocytosis Receptor mediated endocytosis Molecular
1485 Binding of substrate, endocytotic receptor Binding of substrate, endocytotic receptor Molecular
1486 Binding of substrate, endocytic receptor Binding of substrate, endocytic receptor Molecular
1487 Binding, Thiol/seleno-proteins involved in protection against oxidative stress Binding, SH/SeH proteins involved in protection against oxidative stress Molecular
1490 Inhibition, Fatty Acid Beta Oxidation Inhibition of fatty acid beta oxidation Molecular
1495 Substance interaction with the lung resident cell membrane components Interaction with the lung cell membrane Molecular
1502 Histone deacetylase inhibition Histone deacetylase inhibition Molecular
1507 Activation of PPARγ Activation of PPARγ Molecular
1508 CYP2E1 Activation CYP2E1 Activation Molecular
1509 Protein Adduct Formation Protein Adduct Formation Molecular
1510 Oxidative Stress in Brain Oxidative Stress in Brain Molecular
1511 Lipid Peroxidation Lipid Peroxidation Molecular
1512 Unfolded Protein Response Unfolded Protein Response Molecular
1516 Increase, D1 protein antagonism Increase, D1 protein antagonism Molecular
1517 Decrease, Photosystem II activity Decrease, PSII activity Molecular
1522 Inhibition, Chitin synthase 1 Inhibition, CHS-1 Molecular
1525 Increase, Sulfonylurea receptor binding Increase, SUR binding Molecular
1528 Fatty Acid Beta Oxidation, Decreased Fatty Acid Beta Oxidation, Decreased Molecular
1529 Blockade, L-Type Calcium Channels Blockade, L-Type Calcium Channels Molecular
1539 Endocytotic lysosomal uptake endocytosis Molecular
1540 lysosomal disruption lysosom Molecular
1541 Mitochondrial Complex I inhibition Mitochondrial Complex I inhibition Molecular
1542 Increase, Mitochondrial complex III antagonism Increase, Mitochondrial complex III antagonism Molecular
1543 Mitochondrial Complex IV inhibition Mitochondrial Complex IV inhibition Molecular
1544 Mitochondrial Complex V inhibition Mitochondrial Complex V inhibition Molecular
1550 Deposition of Ionizing Energy Ionizing Energy Molecular
1552 Inadequate DNA repair (deprecated, please use https://aopwiki.org/events/155) DNA repair Molecular
1553 Increase mutations Increase mutations Molecular
1554 Increase Chromosomal Aberrations Increase chromosomal aberrations Molecular
1570 Blocking of IL-1R Blocking of IL-1R Molecular
1572 Impaired IL-1 signaling Impaired IL-1 signaling Molecular
1574 Inhibition, IKK complex Inhibition, IKK complex Molecular
1575 Activation, Caspase 8 pathway Activation, Caspase 8 pathway Molecular
1577 Increased, proinflammatory mediators (TNFalpha) Increased, proinflammatory mediators (TNFalpha) Molecular
1579 Increase, proinflammatory mediators (TNFalpha) Increase, proinflammatory mediators (TNFalpha) Molecular
1580 Binding of microtubule stabilizing agents (MSA) to microtubules Binding of MSAs to microtubules Molecular
1584 Interaction of α-diketones with arginine residues Interaction of α-diketones with arginine residues Molecular
1585 Proteasomal dysfunction Proteasomal dysfunction Molecular
1589 Systemic or topical administration of chemicals Administration of chemicals Molecular
1590 Distribution and deposition of chemicals to skin and/or eyes Distribution of chemicals Molecular
1591 Absorption of photon energy Absorption of photon energy Molecular
1592 ROS generation from photoactivated chemicals ROS generation Molecular
1593 Radicals of target chemicals Radical generation Molecular
1602 Activation, Muscarinic Acetylcholine Receptors Activation, Muscarinic Acetylcholine Receptors Molecular
1604 Inhibition of N-linked glycosylation Inhibition of N-linked glycosylation Molecular
1608 Increase, Oxidative DNA damage Increase,Oxidative DNA damage Molecular
1609 Inhibition, Cytochrome P450 enzyme (CYP17A1) activity Inhibition of Cyp17A1 activity Molecular
1617 Inhibition, 5α-reductase Inhibition, 5α-reductase Molecular
1619 Increase, DNA methyltransferase inhibition Increase, DNMT inhibition Molecular
1620 Increase, DNA hypomethylation Increase, DNA hypomethylation Molecular
1621 Increase, Gene expression Increase, Gene expression Molecular
1622 Decrease, Transgenerational DNA methylation Decrease, Transgenerational DNA methylation Molecular
1624 Tyrosinase inhibition leads to L-Dopaquinone reduction tyrosinase, L-Dopaquinone reduction Molecular
1627 Inhibition of tyrosinase tyrosinase Molecular
1632 Increase in reactive oxygen and nitrogen species (RONS) Increase in RONS Molecular
1634 Increase, Oxidative damage to DNA Increase, Oxidative DNA damage Molecular
1635 Increase, DNA strand breaks Increase, DNA strand breaks Molecular
1637 Retinaldehyde dehydrogenase inhibition Retinaldehyde dehydrogenase Molecular
1645 Wnt ligand stimulation Wnt ligand stimulation Molecular
1646 Frizzled activation Frizzled activation Molecular
1647 GSK3beta inactivation GSK3beta inactivation Molecular
1648 β-catenin activation β-catenin activation Molecular
1649 Snail, Zeb, Twist activation Snail, Zeb, Twist activation Molecular
1652 Increase, S-adenosylmethionine depletion Increase, SAM depletion Molecular
1653 Binding of inhibitor to mitochondrial complex III Binding of inhibitor, mitochondrial complex III Molecular
1654 Binding of inhibitor to mitochondrial complex IV Binding of inhibitor, mitochondrial complex IV Molecular
1655 Binding of inhibitor to mitochondrial complex V Binding of inhibitor, mitochondrial complex V Molecular
1656 Antagonism, Thyroid Receptor TR Antagnoism Molecular
1657 Inhibition of cystathionine beta-synthase CBS inhibition Molecular
1658 Inhibition of Methionine synthase Methionine synthase Molecular
1659 Inhibition of Methylenetetrahydrofolate reductase MTHFR inhibition Molecular
1660 Inhibition of betaine-homocysteine methyltransferase betaine-homocysteine methyltransferase inhibition Molecular
1671 Substance - lung surfactant interaction Substance - LS interaction Molecular
1672 Inhibition of lung surfactant function Inhibition of LS function. Molecular
1680 Inhibition, TBX1 Inhibition, TBX1 Molecular
1686 Deposition of Energy Energy Deposition Molecular
1691 Antagonism,LH receptor Antagonism,LH receptor Molecular
1697 Increase, DNA methyltransferase expression Increase, DNMT expression Molecular
1698 Increase, hypermethylation of the promotor region of gonadotropin releasing hormone receptor Increase, hypermethylation of the promotor region of GnRHR Molecular
1699 Decrease, expression of gonadotropin releasing hormone receptor Decease, expression of GnRHR Molecular
1700 Impaired IL-1R1 signaling in T cell Impaired IL-1R1 signaling Molecular
1701 Suppression of NF-kB Suppression of NF-kB Molecular
1704 testJF test Molecular
1706 Stimulation, TLR7/8 Stimulation of TLR7/8 Molecular
1710 Binding to estrogen receptor (ER)-α in immune cells Binding to estrogen receptor (ER)-α Molecular
1715 Inhibition of JAK3 Inhibition of JAK3 Molecular
1720 Trypsin inhibition Inhibition, trypsin Molecular
1725 Pancreatic acinar cell tumors Acinar cell tumors Molecular
1739 Binding to ACE2 Binding to ACE2 Molecular
1740 Induced dysregulation of ACE2 ACE2 enzymatic inhibition Molecular
1753 Chronic reactive oxygen species Chronic ROS Molecular
1765 Increase, Formation of DNA photoproducts Increase, Formation of DNA photoproducts Molecular
1767 Increase, Protein oxidation Increase, Protein oxidation Molecular
1773 Decrease, Global DNA methylation Decrease, Global DNA methylation Molecular
1774 Increase, Caspase transcription Increase, Casp transcription Molecular
1778 Decrease, Heritable DNA methylation (F3) Decrease, Heritable DNA methylation (F3) Molecular
1779 Increase, Caspase transcription (F3) Increase, Casp transcription (F3) Molecular
1785 Increase, Mitochondrial ATP synthase antagonism Increase, Mitochondrial ATP synthase antagonism Molecular
1792 Toll-like receptor 4 activation TLR4 activation Molecular
1796 11β-hydroxylase inhibition 11β-hydroxylase inhibition Molecular
1799 Inhibition of 11β-HSD Inhibition of 11β-HSD Molecular
1806 Inhibition, Chitinase Inhibition, Chitinase Molecular
1807 Inhibition, Chitobiase Inhibition, Chitobiase Molecular
1808 Decrease, ATP synthase activity Decrease, ATP synthase activity Molecular
1811 Increase, Mitochondrial complex III dysfunction Increase, Complex III dysfunction Molecular
1813 Increase, Mitochondrial complex I dysfunction Increase, Complex I dysfunction Molecular
1814 benzoquinone imine and acylglucuronide metabolites Reactive Metabolite Molecular
1827 Increase, Global DNA methylation Increase, Global methylation Molecular
1829 Altered, Thyroid hormone-dependent gene expression Altered, TH-dependent gene expression Molecular
1830 Displacement, Serum thyroxine (T4) from carrier protein Displacement, Serum thyroxine (T4) from carrier protein Molecular
1831 Binding, Thyroid binding globulin in serum Binding, Thyroid binding globulin in serum Molecular
1832 Coordinated gene expression changes by PPARα activation Coordinated gene expression changes Molecular
1834 Decrease, Acyl-CoA dehydrogenases Decrease, ACAD Molecular
1840 Inhibition, cytochrome oxidase Inhibition, cytochrome oxidase Molecular
1842 Prolonged TLR9 activation TLR9 activation Molecular
1848 Toll Like Receptor (TLR) Dysregulation TLR Activation/Dysregulation Molecular
1851 Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R) Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R) Molecular
1853 Hyperactivation of ACE/Ang-II/AT1R axis Hyperactivation of ACE/Ang-II/AT1R axis Molecular
1854 Dysregulation, ACE2 expression and activity ACE2 dysregulation Molecular
1859 Excitation of intracellular water Excitation of intracellular water Molecular
1860 Increase, Excitation of intracellular water Excitation of intracellular water Molecular
1865 Increase, Oxygen-evolving complex damage Increase, OEC damage Molecular
1866 Fibrinolysis, decreased Hypofibrinolysis Molecular
1867 Bradykinin system, hyperactivated Bradykinin, activated Molecular
1879 Bulky DNA adducts, increase Bulky DNA adducts, increase Molecular
1880 Inhibition of ALDH1A (RALDH) ALDH1A (RALDH), inhibition Molecular
1884 Inhibition of Fyna Inhibition of Fyna Molecular
1885 Inhibition of Plxna2 Inhibition of Plxna2 Molecular
1886 Overexpression of rasl11b Overexpression of rasl11b Molecular
1887 Inhibition of CYP26B1 activity CYP26B1, inhibition Molecular
1895 NLRP3 inflammasome activity, increased inflammasome activity, increased Molecular
1897 increased MyD88 activation MyD88 activation Molecular
1902 Repression of Gbx2 expression Repression of Gbx2 expression Molecular
1903 foxi1 expression, increased foxi1 expression, increased Molecular
1904 six1b expression, increased six1b expression, increased Molecular
1905 eya1 expression, inhibited eya1 expression, inhibited Molecular
1906 Cystic Fibrosis Transmembrane Regulator Function, Decreased CFTR Function, Decreased Molecular
1917 Altered gene expression, NRF2 dependent antioxidant pathway Altered expression of NRF2 pathway-dependent genes Molecular
1920 Altered gene expression, TGF-β dependent fibrosis pathway Altered expression of TGF-β fibrosis pathway-dependent genes Molecular
1921 Altered gene expression, NF-kB dependent Interleukin-6 pathway Altered expression of IL-6 pathway-dependent genes Molecular
1923 Altered gene expression, P53 dependent apoptosis pathway Altered expression of P53 pathway-dependent genes Molecular
1935 Angiotensin (1-7) levels diminished Ang (1-7) levels reduced Molecular
1936 Angiotensin II degradation reduced Degradation of Ang-II reduced Molecular
1938 ACE2 increased shedding ACE2 increased shedding Molecular
1940 Increases in cellular reactive oxygen species Increases in cellular ROS Molecular
1948 Increased ACE2 expression Upregulation of ACE2 Molecular
1950 Increase, TNF Increase, TNF Molecular
1956 Binding to hERG channel Binding to hERG channel Molecular
1957 hERG channel biogenesis interference hERG channel biogenesis interference Molecular
1969 Increase, Oxidative Stress Increase, Oxidative Stress Molecular
1984 Agonism, Estrogen Receptor alpha Agonism, Estrogen Receptor alpha Molecular
1985 Increased, Kisspeptin signalling Increased, Kisspeptin signalling Molecular
1986 Decreased, Gonadotropins Decreased, Gonadotropins Molecular
2007 Non-coding RNA expression profile alteration Non-coding RNA expression,alteration Molecular
2020 Decrease, sox9 expression Decrease, sox9 expression Molecular
2021 Increase, slincR expression Increase, slincR expression Molecular
2023 Inhibition of Ceramide Synthase Inhibition CerS Molecular
2027 Antagonism, Smoothened receptor Antagonism Smoothened Molecular
2028 Decrease, GLI1/2 translocation to nucleus Decrease, GLI1/2 translocation Molecular
2029 protein-coupled estrogen receptor 1 (GPER) activation GPER activation Molecular
2030 Activation, PARP1 PARP1 Molecular
2031 Releasing, Apoptosis-Inducing Factor (AIF) AIF release Molecular
2036 Activation of metabotropic glutamate receptor Activation, mGLUr Molecular
2037 Inositol triphosphate receptor activation Activation, IP3R Molecular
2039 Inhibition GABAA receptor Inhibition, GABAAr Molecular
2045 Increase, Alcohol dehydrogenase Increase, Alcohol dehydrogenase Molecular
2046 Increase, Vitellogenin mRNA Increase, Vitellogenin mRNA Molecular
2051 Decrease, Tyrosine Decrease, Tyrosine Molecular
2058 Decrease, 20-hydroxyecdysone Decrease, 20-hydroxyecdysone Molecular
2066 Altered Signaling Pathways Altered Signaling Molecular
2073 increase oxidation of the di-copper moiety of the hemocyanin active site methemocyanin formation (decrease overall oxygen binding capacity) Molecular
2074 Decreased, oxygen binding capacity by hemocyanin Decrease overall oxygen binding capacity (methemocyanin formation) Molecular
2081 Increased Modified Proteins Modified Proteins Molecular
2099 hERG channel blockade hERG channel blockade Molecular
2101 Conformational changes of thyroid receptor Conformational changes of thyroid receptor Molecular
2104 Decreased, thyroid hormone binding to thyroid hormone receptor Decreased, TH binding to THR Molecular
2105 Decreased, myelin basic protein expression in oligodendrocytes Decreased, mbp expression in oligodendrocytes Molecular
2109 Binding, extracellular matrix protein laminin Binding to laminin Molecular
2110 Disrupted binding, laminin-beta1-integrin receptors with laminin binding beta1integrin receptors with laminin Molecular
2115 Altered, cholesterol metabolism Cholesterol metabolism Molecular
2118 Succinate dehydrogenase, inhibited SDH, inhibited Molecular
2123 decreased, Bcl-2 expression decreased, Bcl-2 Molecular
2124 increased, Bax expression increased, Bax Molecular
2126 Estrogen receptor alpha inactivation ERa inactivation Molecular
2133 Increase, Glucuronidation of T4 Increase, Glucuronidation of T4 Molecular
2134 Increase, Androgen receptor Increase, Androgen receptor Molecular
2141 Disruption, Estrogen receptor Disruption of ER Molecular
2143 Increased, gene expression of AR Increased, gene expression of AR Molecular
2146 Activation of mitogen-activated protein kinase kinase, extracellular signal-regulated kinase 1/2 Activation of MEK, ERK1/2 Molecular
2148 Increased LCN2/iron complex binds to SLC22A17 receptor in neuron Increased LCN2/iron complex Molecular
2151 Disruption, neurotransmitter release Disruption, neurotransmitter release Molecular
2155 Inhibition of Sulfotransferase E1 (SULT1E1) SULT1E1 inhibition Molecular
2158 Influenza A Virus (IAV) binds sialic acid glycan receptor IAV binds receptor Molecular
2170 Activated ANG/Tie2 pathway Activated ANG/Tie2 pathway Molecular
2180 Immune mechanisms antagonized by viral proteins immune mechanisms antagonized Molecular
2186 Ryanodine receptor activation Activation, RyR Molecular
2187 Opening, voltage-gated calcium channels Opening VGCCs Molecular
2192 Influenza A Virus production increased IAV production increased Molecular
2196 Decrease, elavl3 Decrease, elavl3 Molecular
2197 Decrease, sox10 Decrease, sox10 Molecular
2198 Decrease, mbp Decrease, mbp Molecular
2199 Increased, Expression of LXR activated genes Increased, Expression of LXR activated genes Molecular
2201 Agonism, Retinoic acid receptor RAR agonism Molecular
2202 Altered expression of cell cycle genes Altered expression of cell cycle genes Molecular
2205 Increased, essential element imbalance Increased, essential element imbalance Molecular
39 Increased Cholinergic Signaling Increased Cholinergic Signaling Organ
129 Reduction, Gonadotropins, circulating concentrations Reduction, Gonadotropins, circulating concentrations Organ
161 Increase, Liver and splenic hemosiderosis Increase, Liver and splenic hemosiderosis Organ
164 Induction, Liver “Dysfunctional” Changes by CGA 330050 Induction, Liver “Dysfunctional” Changes by CGA 330050 Organ
166 Decreased, Long-term potentiation (LTP) Decreased, Long-term potentiation (LTP) Organ
173 N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number Organ
186 Altered, Neuroanatomy Altered, Neuroanatomy Organ
192 Altered, Neurophysiology Altered, Neurophysiology Organ
219 Reduction, Plasma 17beta-estradiol concentrations Reduction, Plasma 17beta-estradiol concentrations Organ
220 Increase, Plasma vitellogenin concentrations Increase, Plasma vitellogenin concentrations Organ
221 Reduction, Plasma vitellogenin concentrations Reduction, Plasma vitellogenin concentrations Organ
240 Feminisation or incomplete development, Primary and accessory male sex organs Feminisation or incomplete development, Primary and accessory male sex organs Organ
246 Increase, RBC congestion in liver Increase, RBC congestion in liver Organ
252 Increase, Renal pathology due to VTG deposition Increase, Renal pathology due to VTG deposition Organ
272 Activation/Proliferation, T-cells Activation/Proliferation, T-cells Organ
280 Thyroxine (T4) in neuronal tissue, Decreased T4 in neuronal tissue, Decreased Organ
313 Increase, Allergic Respiratory Hypersensitivity Response Increase, Allergic Respiratory Hypersensitivity Response Organ
317 Altered, Cardiovascular development/function Altered, Cardiovascular development/function Organ
319 Loss, Cochlear function Loss, Cochlear function Organ
327 Accumulation, Fatty acid Accumulation, Fatty acid Organ
344 N/A, Liver fibrosis N/A, Liver fibrosis Organ
345 N/A, Liver Steatosis N/A, Liver Steatosis Organ
348 Malformation, Male reproductive tract Malformation, Male reproductive tract Organ
358 Increase, Pericardial edema Increase, Pericardial edema Organ
386 Decrease of neuronal network function Neuronal network function, Decreased Organ
401 Increase, Biliary excretion TH glucuronide Increase, Biliary excretion TH glucuronide Organ
419 Increased, renal vitellogenin deposition Increased, renal vitellogenin deposition Organ
421 Increased, glomerular rupture and renal hemorrhaging Increased, glomerular rupture and renal hemorrhaging Organ
444 Increased, Atrioventricular block and bradycardia Increased, Atrioventricular block and bradycardia Organ
445 Respiratory distress/arrest Respiratory distress/arrest Organ
455 Accumulation, Liver lipid Accumulation, Liver lipid Organ
459 Increased, Liver Steatosis Increased, Liver Steatosis Organ
486 systemic inflammation leading to hepatic steatosis inflammation Organ
488 Decrease, Ovulation Decrease, Ovulation Organ
491 Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF) Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF) Organ
540 Decreased testosterone by the fetal Leydig cells, Dysgensis of fetal Leydig cells Decreased testosterone by the fetal Leydig cells, Dysgensis of fetal Leydig cells Organ
602 Increased, Ataxia, paralysis, or hyperactivity Increased, Ataxia, paralysis, or hyperactivity Organ
618 Decreased, Neuronal network function in adult brain Decreased, Neuronal network function in adult brain Organ
625 Increased, muscular waves in foot Increased, muscular waves in foot Organ
646 Decreased Cholesterol, Decreased sperm quantity and/or quality in the adult testis Decreased Cholesterol, Decreased sperm quantity and/or quality in the adult testis Organ
657 Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells Organ
660 decreased testosterone by fetal Leydig cells, Dysgenesis of fetal Leydig cells decreased testosterone by fetal Leydig cells, Dysgenesis of fetal Leydig cells Organ
672 Reduced, Prostaglandin F2alpha synthesis, ovary Reduced, Prostaglandin F2alpha synthesis, ovary Organ
681 Decreased, Prostaglandin F2alpha synthesis, ovary Decreased, Prostaglandin F2alpha synthesis, ovary Organ
685 Reduced, Prostaglandins, ovary Reduced, Prostaglandins, ovary Organ
699 Increased, cardiac arrthymia Increased, cardiac arrthymia Organ
764 N/A, Ataxia, paralysis, or hyperactivity N/A, Ataxia, paralysis, or hyperactivity Organ
793 Increase, Urinary bladder calculi Increase, Urinary bladder calculi Organ
813 Increased, Serum creatinine Increased, Serum creatinine Organ
814 Occurrence, Kidney toxicity Occurrence, Kidney toxicity Organ
818 Occurrence, Cytoplasmic vacuolization (Renal tubule) Occurrence, Cytoplasmic vacuolization (Renal tubule) Organ
821 Decreased, Sodium reabsorption Decreased, Sodium reabsorption Organ
823 Occurrence, Cystic dilatation (renal tubule) Occurrence, Cystic dilatation (renal tubule) Organ
824 Occurrence, Cytoplasmic vacuolization (podocyte) Occurrence, Cytoplasmic vacuolization (podocyte) Organ
825 Decreased, Renal ability to dilute urine Decreased, Renal ability to dilute urine Organ
827 sensitisation, skin sensitisation, skin Organ
846 Accumulation, Highly carboxylated porphyrins Accumulation, Highly carboxylated porphyrins Organ
856 Formation, Hepatocellular and Bile duct tumors Formation, Hepatocellular and Bile duct tumors Organ
863 Increased, Catabolism of Muscle Protein Increased, Catabolism of Muscle Protein Organ
872 Increase, Site of Contact Nasal Tumors Increase, Site of Contact Nasal Tumors Organ
890 Degeneration of dopaminergic neurons of the nigrostriatal pathway Degeneration of dopaminergic neurons of the nigrostriatal pathway Organ
902 Inflammation, Liver Inflammation, Liver Organ
937 KE7 : Impaired, Vasodilation Impaired, Vasodilation Organ
943 Hypersecretion, Mucus Hypersecretion, Mucus Organ
951 KE8 : Increase, Vascular Resistance Increase, Vascular Resistance Organ
967 Decreased positive estrogenic feedback on hypothalamus, Reduced estradiol in circulation decreases estrogen concentration at hypothalamus Decreased positive estrogenic feedback on hypothalamus, Reduced estradiol in circulation de Organ
996 Decrease, Digestion of old cuticle Decrease, Digestion of old cuticle Organ
1004 Reduced, Posterior swim bladder inflation Reduced, Posterior swim bladder inflation Organ
1007 Reduced, Anterior swim bladder inflation Reduced, Anterior swim bladder inflation Organ
1008 Reduced, Hearing Reduced, Hearing Organ
1058 Decreased, bile flow Decreased, bile flow Organ
1059 Increased, cholestasis Increased, cholestasis Organ
1063 Increased, Pancreatic acinar tumors Increased, Pancreatic acinar tumors Organ
1076 Increased, circulating estrogen levels Increased, circulating estrogen levels Organ
1101 Altered, Amphibian metamorphosis Altered, Amphibian metamorphosis Organ
1106 Occurrence, cardiac arrhythmia Occurrence, cardiac arrhythmia Organ
1130 Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage) Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage) Organ
1139 Increased, water retention in foot Increased, water retention in foot Organ
1161 Increased, oocyte maturation Increased, oocyte maturation Organ
1209 Induction, Male reproductive tract Induction, Male reproductive tract Organ
1217 Excitation of trigeminal nerves induces Sensory Airway Irritation, Sensory Airway Irritation Organ
1226 Increased Respiratory irritability and Chronic Cough, Respiratory irritability Organ
1256 increased mantel display increased mantel display Organ
1276 Lung fibrosis Lung fibrosis Organ
1311 Inhibition, Steatosis Inhibition, Steatosis Organ
1366 Decrease, Oogenesis Decrease, Oogenesis Organ
1367 Inhibit, gastric ulcer formation Inhibit, gastric ulcer formation Organ
1385 Activated, gastric ulcer formation Activated, gastric ulcer formation Organ
1395 Liver Cancer Liver Cancer Organ
1418 Increased, steatosis Increased, steatosis Organ
1438 Transcription of genes encoding acute phase proteins, Increased Increased transcription of genes encoding acute phase proteins Organ
1439 Systemic acute phase response Systemic acute phase response Organ
1441 Increased systemic total cholesterol pool Systemic cholesterol increased Organ
1442 Foam cell formation Foam cell formation Organ
1444 Increase, Follicular atresia Increase, Follicular atresia Organ
1458 Pulmonary fibrosis Pulmonary fibrosis Organ
1466 Notochord distortion or malformations Notochord malformation Organ
1479 Decrease, Leaf development Decrease, Leaf development Organ
1480 Increase, Growth hormone Increase, Growth hormone Organ
1489 N/A, Steatohepatisis steatohepatitis Organ
1506 Testicular atrophy Testicular atrophy Organ
1514 Neurodegeneration Neurodegeneration Organ
1532 Decrease, Cardiac contractility Decrease, Cardiac contractility Organ
1533 Decrease, Cardiac ejection fraction Decrease, Cardiac ejection fraction Organ
1535 Heart failure Heart failure Organ
1549 Liver Injury Liver Injury Organ
1556 Increase, lung cancer Increase, lung cancer Organ
1567 Suppressed DC activation Suppressed DC activation Organ
1568 Impaired antigen presentation Impaired antigen presentation Organ
1599 Inflamatory events in light-exposed tissues Inflammatory events Organ
1600 Eczematous eruption (Erythema, Papules, Vesicles, Pruritius, Weeping, Oozing, Crusting) Eczematous eruption Organ
1601 Scaling, Lichenification Scaling, Lichenification Organ
1603 Chronic kidney disease Chronic kidney disease Organ
1615 Impaired inguinoscrotal testicular descent phase Impaired inguinoscrotal phase Organ
1616 Malformation, cryptorchidism - maldescended testis Malformation, cryptorchidism Organ
1643 Altered, Visual function Altered, Visual function Organ
1663 Increased brain Homocysteine level brain Homocysteine level increases Organ
1666 Induced, dysfunction of microcirculation dysfunction of microcirculation Organ
1670 Lung cancer Lung cancer Organ
1676 Blood extravasation into the lungs Blood extravasation into the lungs Organ
1677 Reduced tidal volume Reduced tidal volume Organ
1678 Impaired oxygenation of the blood Impaired oxygenation of the blood Organ
1684 Abnormalities, Cardiac outflow tract formation Abnormalities, Cardiac outflow tract formation Organ
1695 Impaired ovulation Impaired ovulation Organ
1703 Dysregulation of heart rate and vascular tone Cardiovascular dysregulation Organ
1721 Increased intestinal monitor peptide level Increased monitor peptide Organ
1722 Increased blood CCK level Increased blood CCK level Organ
1746 Induction lung fibrosis Induction lung fibrosis Organ
1748 Increase, the risk of acute respiratory failure Increase, the risk of acute respiratory failure Organ
1758 Impaired, Spermatogenesis Impaired, Spermatogenesis Organ
1763 Urothelial Tumor carcinogenicity Organ
1777 Increase, Ovarian follicle breakdown Increase, Ovarian follicle breakdown Organ
1782 Decrease, Oogenesis (F3) Decrease, Oogenesis (F3) Organ
1784 Increase, Ovarian follicle breakdown (F3) Increase, Ovarian follicle breakdown (F3) Organ
1798 Decreased spermatogenesis Decreased spermatogenesis Organ
1809 Increase, Tissue/organ damage Increase, Tissue/organ damage Organ
1820 Immune mediated hepatitis hepatitis Organ
1828 Increased, Thyroxine (T4) in serum Increased, Thyroxine (T4) in serum Organ
1837 decreased oocyte maturation decreased oocyte maturation Organ
1839 Testicular Cancer Testicular Cancer Organ
1841 Encephalitis Encephalitis Organ
1845 Coagulation Coagulation Organ
1850 dysgeusia taste impairment Organ
1873 impaired olfactory function (anosmia) anosmia Organ
1875 Cerebrovascular disease (stroke) stroke Organ
1878 Decreased, Eye size Decreased, Eye size Organ
1883 Reduced size of the ovarian follicle pool Ovarian follicle pool, reduced Organ
1892 increase, placental insufficiency increase, placental insufficiency Organ
1910 Mucus Viscosity, Increased Mucus Viscosity, Increased Organ
1916 Thromboinflammation, Increased Thromboinflammation, Increased Organ
1924 Increased,Cardiac fibrosis Increased,Cardiac fibrosis Organ
1930 altered, inner ear development Altered, inner ear development Organ
1931 Intestinal barrier, disruption Disruption of the intestinal barrier Organ
1934 Myocardial Infarction Heart attack Organ
1944 Synaptic dysfunction Dysfunctional synapses Organ
1952 Abnormal, Glucose homeostasis Abnormal, Glucose homeostasis Organ
1954 Gut microbiota, alteration Gut dysbiosis Organ
1961 Prolongation of Action Potential Duration Prolongation of Action Potential Organ
1962 Prolongation of QT interval Prolongation of QT interval Organ
1963 Torsades de Pointes Torsades de Pointes Organ
1965 Increase, Pollen abnormal Increase, Pollen abnormal Organ
1970 transposition of the great arteries Transposition of the great arteries Organ
1971 Increased, tumor growth tumor growth Organ
1979 Premature cell differentiation Premature differentiation Organ
1982 metastatic breast cancer Metastasis, Breast Cancer Organ
1993 Increase, Pneumonia Pneumonia Organ
1997 Colon epithelial injury Colon epithelial injury Organ
2000 Vascular calcification Vascular calcification Organ
2001 Cardiac hypertrophy Cardiac hypertrophy Organ
2002 Ventricular remodeling Ventricular remodeling Organ
2003 Vascular remodeling Vascular remodeling Organ
2010 Pulmonary inflammation Pulmonary inflammation Organ
2011 Emphysema Emphysema Organ
2013 Airway remodeling Airway remodeling Organ
2015 Intestinal inflammation Intestinal inflammation Organ
2022 Altered function of the brain brain function Organ
2034 liver dysfunction liver dysfunction Organ
2062 Weak, Procuticle protection Weak, Procuticle protection Organ
2063 Decrease, New cuticle secretion Decrease, New cuticle secretion Organ
2069 Occurrence, Vascular Remodeling Occurrence, Vascular Remodeling Organ
2075 Cognitive, sensed as hypoxic/low oxygen environment Hemocyanin Bohr effect decrease Organ
2080 Impaired, blood testis barrier Impaired, blood testis barrier Organ
2082 Hypospadias, increased Hypospadias Organ
2083 Occurrence of Cataracts Cataracts Organ
2086 Airway inflammation Airway inflammation Organ
2091 Occurrence, Bone Loss Bone Loss Organ
2092 Promotion, Ovarian Cancer Promotion, Ovarian Cancer Organ
2093 Brain thyroid hormone (T4/T3) decreased Decreased brain T4/T3 Organ
2114 Disturbed, cortical architecture Disturbed cortical architecture Organ
2125 Increased fat mass Increased fat mass Organ
2139 Reduction, the ratio of 17beta-estradiol/11-Keto Testosterone in plasma Reduction, the ratio of E2/11-KT in plasma Organ
2154 Uterine adenocarcinoma (endometrioid adenocarcinoma Type I) endometrioid adenocarcinoma Type I Organ
2157 Abnormal Cardiac Structure and Function Abnormal Cardiac Structure and Function Organ
2160 Angiogenesis disfunction Angiogenesis disfunction Organ
2181 Angiogenesis dysfunction Angiogenesis dysfunction Organ
2200 decline, neural progenitor cells decline, neural progenitor cells Organ
2204 Altered brain morphology Altered brain morphology Organ
2208 Aberrant, synaptic formation and plasticity Aberrant, synaptic formation and plasticity Organ
2211 Microcephaly Microcephalus Organ
351 Increased Mortality Increased Mortality Population
360 Decrease, Population growth rate Decrease, Population growth rate Population
361 Decline, Population Decline, Population Population
417 skewed, sex ratio skewed, sex ratio Population
442 Decreased, Population trajectory Decreased, Population trajectory Population
561 Reduced, Food storage Reduced, Food storage Population
563 Death/Failure, Colony Death/Failure, Colony Population
564 Abnormal, Roll change within caste Abnormal, Roll change within caste Population
565 Reduced, Brood care Reduced, Brood care Population
566 impaired, Larval development impaired, Larval development Population
568 impaired, Hive thermoregulation impaired, Hive thermoregulation Population
572 Decrease, Number of worker bees Decrease, Number of worker bees Population
580 Reduced, Antiseptic incorporated in food Reduced, Antiseptic incorporated in food Population
588 Increased, predation Increased, predation Population
592 Reduced, survival Reduced, survival Population
623 Increase, predation Increase, predation Population
636 Decreased, survival Decreased, survival Population
679 Decline, Population trajectory Decline, Population trajectory Population
759 Increased, Kidney Failure Increased, Kidney Failure Population
765 Decreased, population 1 Decreased, population 1 Population
997 Decreased, Population size Decreased, Population size Population
1107 Weakened, Colony Weakened, Colony Population
1108 Abnormal, Role change within caste Abnormal, Role change within caste Population
1136 Impaired recruitment , Population trajectory Impaired recruitment , Population trajectory Population
1164 Increased, Population Increased, Population Population
1208 Increased, Male offspring Increased, Male offspring Population
1210 Alteration, Food-web structures Alteration, Food-web structures Population
1211 Altered, food-web structures Altered, food-web structures Population
1791 Increased, Male Biased Sex Ratio Increased, Male Biased Sex Ratio Population
1929 Increased incidence of cardiovascular morbidity and mortality in the general population Increased incidence of cardiovascular morbidity and mortality Population
1991 Impaired, Reproduction Impaired, Reproduction Population
1992 Increased incidence of respiratory morbidity and mortality in the general population Increased incidence of respiratory morbidity and mortality Population
1996 Increased incidence of digestive morbidity and mortality in the general population Increased incidence of digestive morbidity and mortality Population
1999 Increased mortality of neurodegenerative diseases Increased mortality of neurodegenerative diseases Population
2121 decreased, Intellectual Quotient decreased, IQ Population
2122 increased, socio-economic burden increased, Economic Burden Population
2145 Metabolic syndrome Metabolic syndrome Population
2156 Increased morbidity of congenital heart defect Increased morbidity of congenital heart defect Population
2183 Increased incidence of vascular calcification and atherosclerosis morbidity Increased incidence of vascular calcification and atherosclerosis morbidity Population
49 Reduction, Ca and HCO3 transport to shell gland Reduction, Ca and HCO3 transport to shell gland Tissue
68 Accumulation, Collagen Accumulation, Collagen Tissue
106 Reduction, Eggshell thickness Reduction, Eggshell thickness Tissue
119 N/A, Gap N/A, Gap Tissue
139 N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects Tissue
142 Hyperplasia, Hyperplasia Hyperplasia, Hyperplasia Tissue
188 Neuroinflammation Neuroinflammation Tissue
243 Reduction, Prostaglandin E2 concentration Reduction, Prostaglandin E2 concentration Tissue
249 Production, Reactive oxygen species Production, Reactive oxygen species Tissue
281 Thyroxine (T4) in serum, Decreased T4 in serum, Decreased Tissue
285 Reduction, Vitellogenin synthesis in liver Reduction, Vitellogenin synthesis in liver Tissue
286 Altered, Transcription of genes by the androgen receptor Altered, Transcription of genes by the AR Tissue
307 Increase, Vitellogenin synthesis in liver Increase, Vitellogenin synthesis in liver Tissue
352 N/A, Neurodegeneration N/A, Neurodegeneration Tissue
446 Reduction, fetal/adult testosterone Reduction of testosterone Tissue
590 N/A, hypoxia N/A, hypoxia Tissue
601 Overactivation, muscle contraction Overactivation, muscle contraction Tissue
616 Occurrence, A paroxysmal depolarizing shift Occurrence, A paroxysmal depolarizing shift Tissue
621 Increase, cilia movement Increase, cilia movement Tissue
648 Decreased steroidogenesis, Increased Apoptosis of Adult Leydig Cells Decreased steroidogenesis, Increased Apoptosis of Adult Leydig Cells Tissue
649 Decreased steroidogenesis, Alterations in the Leydig Cell Cytoskeleton Decreased steroidogenesis, Alterations in the Leydig Cell Cytoskeleton Tissue
687 Reduced, Prostaglandin E2 concentration, hypothalamus Reduced, Prostaglandin E2 concentration, hypothalamus Tissue
689 Reduced, Gonadotropin releasing hormone, hypothalamus Reduced, Gonadotropin releasing hormone, hypothalamus Tissue
690 Reduced, Luteinizing hormone (LH), plasma Reduced, Luteinizing hormone (LH), plasma Tissue
691 Reduced, Maturation inducing steroid, plasma Reduced, Maturation inducing steroid, plasma Tissue
692 Reduced, Maturation inducing steroid receptor signalling, oocyte Reduced, Maturation inducing steroid receptor signalling, oocyte Tissue
693 Increased, cyclic adenosine monophosphate Increased, cyclic adenosine monophosphate Tissue
708 Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium) Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium) Tissue
713 Increase, Adenomas/carcinomas (renal tubular) Increase, Adenomas/carcinomas (renal tubular) Tissue
719 Increase, hepatocellular adenomas and carcinomas Increase, hepatocellular adenomas and carcinomas Tissue
736 Increase, Adenomas/carcinomas (bronchioloalveolar) Increase, Adenomas/carcinomas (bronchioloalveolar) Tissue
741 Increase, Adenomas/carcinomas (follicular cell) Increase, Adenomas/carcinomas (follicular cell) Tissue
747 Decreased, Prolactin Decreased, Prolactin Tissue
749 Decreased, Progesterone from corpus luteum Decreased, Progesterone from corpus luteum Tissue
753 Increase, Thyroid-stimulating hormone (TSH) Increase, Thyroid-stimulating hormone (TSH) Tissue
754 Increased, Luteinizing hormone (LH) Increased, Luteinizing hormone (LH) Tissue
756 Hippocampal gene expression, Altered Hippocampal gene expression, Altered Tissue
757 Hippocampal anatomy, Altered Hippocampal anatomy, Altered Tissue
758 Hippocampal Physiology, Altered Hippocampal Physiology, Altered Tissue
771 Decrease, Serum thyroid hormone (T4/T3) Decrease, Serum thyroid hormone (T4/T3) Tissue
773 Increase, Endometrial adenocarcinomas Increase, Endometrial adenocarcinomas Tissue
775 Increased, Plasma tyrosine Increased, Plasma tyrosine Tissue
791 Increased, Leutinizing hormone (LH) Increased, Leutinizing hormone (LH) Tissue
792 Decrease, Bioactivation of testosterone Decrease, Bioactivation of testosterone Tissue
797 Increase, Adenomas/carcinomas (urothelial) Increase, Adenomas/carcinomas (urothelial) Tissue
807 Decreased, cholesterol Decreased, cholesterol Tissue
819 Decreased, Glomerular filtration Decreased, Glomerular filtration Tissue
820 Decreased, Renal plasma flow Decreased, Renal plasma flow Tissue
838 Induction, Microvesicular fat Induction, Microvesicular fat Tissue
840 Formation, Liver fibrosis Formation, Liver fibrosis Tissue
854 Alterations, Cellular proliferation / hyperplasia Alterations, Cellular proliferation / hyperplasia Tissue
862 Not Increased, Circulating Ketone Bodies Not Increased, Circulating Ketone Bodies Tissue
868 Increase, Tissue Degeneration, Necrosis & Atrophy Increase, Tissue Degeneration, Necrosis & Atrophy Tissue
869 Increase, Respiratory or Squamous Metaplasia Increase, Respiratory or Squamous Metaplasia Tissue
880 Increased, ApoB100 Increased, ApoB100 Tissue
885 Increase, Cancer Increase, Cancer Tissue
901 Infiltration, Inflammatory cells Infiltration, Inflammatory cells Tissue
920 Occurrence, Metaplasia of goblet cells Goblet cell metaplasia Tissue
921 Occurrence, Hyperplasia of goblet cells Goblet cell hyperplasia Tissue
959 Increased, Free serum thyroxine (T4) Increased, Free serum thyroxine (T4) Tissue
961 Increased, Clearance of thyroxine from serum Increased, Clearance of thyroxine from serum Tissue
966 Reduced Estradiol in Circulation, Reduced steroidogenic production of estradiol in granulosa cells leading to decreased estradiol in circulation Reduced Estradiol in Circulation, Reduced steroidogenic production of estradiol in granulos Tissue
988 Decrease, Circulating ecdysis triggering hormone Decrease, Circulating ETH Tissue
993 Decrease, Abdominal muscle contraction Decrease, Abdominal muscle contraction Tissue
994 Decreased, Synthesis of molting fluid proteases Decreased, Synthesis of molting fluid proteases Tissue
1003 Decreased, Triiodothyronine (T3) Decreased, Triiodothyronine (T3) Tissue
1014 Induction, Somatic muscle paralysis Induction, Somatic muscle paralysis Tissue
1019 Induction, pharyngeal muscle paralysis Induction, pharyngeal muscle paralysis Tissue
1022 Decreased, serum T4/T3 Decreased, serum T4/T3 Tissue
1023 Increased, Thyroid-stimulating hormone (TSH) Increased, Thyroid-stimulating hormone (TSH) Tissue
1025 Increased, Hyperplasia (follicular cells) Increased, Hyperplasia (follicular cells) Tissue
1026 Increased Apoptosis, Adenomas/carcinomas (follicular cell) Increased Apoptosis, Adenomas/carcinomas (follicular cell) Tissue
1035 Increased, Firbrosarcoma Increased, Firbrosarcoma Tissue
1036 Increased, liposarcoma Increased, liposarcoma Tissue
1037 Increased, hemagiosarcoma Increased, hemagiosarcoma Tissue
1040 relaxation, smooth muscle relaxation, smooth muscle Tissue
1044 Promotion, mesovarian leiomyomas Promotion, mesovarian leiomyomas Tissue
1045 Decreased, Ovarian E2 Decreased, Ovarian E2 Tissue
1052 Hyperplasia, ovarian epithelium Hyperplasia, ovarian epithelium Tissue
1053 Promotion, ovarian adenomas Promotion, ovarian adenomas Tissue
1056 Decrease, E2 blood concentrations at hypothalamus Decrease, E2 blood concentrations at hypothalamus Tissue
1061 prolonged, elevation of serun CCK prolonged, elevation of serun CCK Tissue
1068 squamous metaplasia, aberrant basal cells squamous metaplasia, aberrant basal cells Tissue
1070 Increased, adenosquamous carcinomas of endometrium Increased, adenosquamous carcinomas of endometrium Tissue
1077 Increased, prolactin exposure Increased, prolactin exposure Tissue
1078 Hyperplasia, Mammary gland Hyperplasia, Mammary gland Tissue
1079 Increased, Adenomas/carcinomas (mammary) Increased, Adenomas/carcinomas (mammary) Tissue
1082 Increased, adenomas (pituitary) Increased, adenomas (pituitary) Tissue
1084 Increased, prolactin secretion Increased, prolactin secretion Tissue
1085 Increased, hyperplasia (mammary gland) Increased, hyperplasia (mammary gland) Tissue
1090 Increased, mesotheliomas Increased, mesotheliomas Tissue
1093 Decreased, Thyroxine (T4) in tissues Decreased, Thyroxine (T4) in tissues Tissue
1096 Increased, blood uric acid concentration Increased, blood uric acid concentration Tissue
1097 Occurrence, renal proximal tubular necrosis Occurrence, renal proximal tubular necrosis Tissue
1098 Increased, blood potassium concentration Increased, blood potassium concentration Tissue
1102 Occurrence, tophi (urate) deposition Occurrence, tophi (urate) deposition Tissue
1104 Decreased, Prostaglandin F2alpha concentration, plasma Decreased, Prostaglandin F2alpha concentration, plasma Tissue
1105 Occurrence, renal ischemia Occurrence, renal ischemia Tissue
1116 Decreased, Triiodothyronine (T3) in tissues Decreased, Triiodothyronine (T3) in tissues Tissue
1122 Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur Tissue
1133 Hemostasis, Depletion from blood of fully functional carboxylated clotting factors Hemostasis, Depletion from blood of fully functional carboxylated clotting factors Tissue
1135 Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction Tissue
1142 Increased, valve movement Increased, valve movement Tissue
1154 Increased, Triiodothyronine (T3) in tissues Increased, Triiodothyronine (T3) in tissues Tissue
1158 Increased, Hepatic thyroid hormone uptake/transport Increased, Hepatic thyroid hormone uptake/transport Tissue
1166 Increased, water pumping Increased, water pumping Tissue
1192 Increased, Ductal Hyperplasia Increased, Ductal Hyperplasia Tissue
1203 Suppression, Suppression of production of cytotoxic T-cells Suppression, Suppression of production of cytotoxic T-cells Tissue
1220 Trigeminal nerve activation Excitation, Trigeminal nerve excitation Tissue
1223 Trigeminal and/or vagal nerve excitation causes Airway Hyper-responsiveness,Cough, Dyspnea Increased Airway Hyper-responsiveness,Cough, Dyspnea Tissue
1225 Immune system inflammation Leukocyte infiltration Tissue
1234 Production of nerve growth factor , Epithelial irritation Production of nerve growth factor , Epithelial irritation Tissue
1235 Non-neuronal production of IL-8/CXCL1, Epithelial irritation Non-neuronal production of IL-8/CXCL1, Epithelial irritation Tissue
1251 Chronic, Mucus hypersecretion Chronic, Mucus hypersecretion Tissue
1263 Necrosis Necrosis Tissue
1266 Decrease, Circulating crustacean cardioactive peptide Decrease, Circulating CCAP Tissue
1267 Decrease, Ecdysis motoneuron bursts Decrease, Ecdysis motoneuron bursts Tissue
1268 Decrease, Excitatory postsynaptic potential Decrease, Excitatory postsynaptic potential Tissue
1275 Collagen Deposition Collagen Deposition Tissue
1295 Defect of Embryogenesis Defect of Embryogenesis Tissue
1374 Increase, mucosal blood flow Increase, mucosal blood flow Tissue
1375 Increase, platelet aggregation Increase, platelet aggregation Tissue
1376 Increase, angiogenesis Increase, angiogenesis Tissue
1377 Decrease, leukocyte adherence Decrease, leukocyte adherence Tissue
1378 Increase, leukocyte adherence Increase, leukocyte adherence Tissue
1380 Activate, mucosal defense Activate, mucosal defense Tissue
1388 Dopamine release in the brain, decreased Dopamine release in the brain, decreased Tissue
1401 Decreased, 5-HT3 Decreased, 5-HT3 Tissue
1403 Reduced, platelet aggregation Reduced, platelet aggregation Tissue
1404 Decreased, mucosal blood flow Decreased, mucosal blood flow Tissue
1405 Reduced, mucosal defense Reduced, mucosal defense Tissue
1406 Decreased, mucous Decreased, mucous Tissue
1407 Decreased, bicarbonate Decreased, bicarbonate Tissue
1409 Decreased, angiogenesis Decreased, angiogenesis Tissue
1410 Increased, leukocyte adherence Increased, leukocyte adherence Tissue
1411 Increased, leukocyte activation Increased, leukocyte activation Tissue
1412 Helicobacter pylori infection Helicobacter pylori infection Tissue
1434 Irritation of nasal mucosa inducing sneeze reflex Irritation induced sneezing Tissue
1449 increased adipogenesis increased adipogenesis Tissue
1464 Reduction of collagen crosslinking Reduction of collagen crosslinking Tissue
1465 Weak collagen matrix Weak collagen matrix Tissue
1478 Decrease, Leaf cell mitosis Decrease, Leaf cell mitosis Tissue
1491 Increased, Oncotic Necrosis increased, oncotic necrosis Tissue
1493 Increased Pro-inflammatory mediators Increased pro-inflammatory mediators Tissue
1497 Increased, recruitment of inflammatory cells Recruitment of inflammatory cells Tissue
1498 Loss of alveolar capillary membrane integrity Loss of alveolar capillary membrane integrity Tissue
1499 Increased, activation of T (T) helper (h) type 2 cells Activation of Th2 cells Tissue
1500 Increased, fibroblast proliferation and myofibroblast differentiation Increased cellular proliferation and differentiation Tissue
1501 Increased, extracellular matrix deposition Increased extracellular matrix deposition Tissue
1515 Spermatocyte depletion Spermatocyte depletion Tissue
1523 Decrease, Cuticular chitin content Decrease, Cuticular chitin content Tissue
1548 Necrotic Tissue Necrotic Tissue Tissue
1558 Collagen production, reduced Reduced collagen production Tissue
1559 Facial cartilage structures are reduced in size and morphologically distorted Smaller and morphologically distorted facial cartilage structures Tissue
1561 Neural tube defects Neural tube defects Tissue
1563 Decreased proximal tubular vectorial transport Decreased proximal tubular vectorial transport Tissue
1578 Increase, Necrotic tissue Increase, Necrotic tissue Tissue
1587 Fibroproliferative airway lesions Fibroproliferative airway lesions Tissue
1607 Increase, Necrosis Increase, Necrosis Tissue
1613 Decrease, dihydrotestosterone (DHT) level Decrease, DHT level Tissue
1614 Decrease, androgen receptor activation Decrease, AR activation Tissue
1623 Occurrence, Focal Seizure Occurrence, Focal Seizure Tissue
1626 reduction in melanin lead to decrease of pigmentation melanin, pigmentation Tissue
1630 Reduction of melanosome level Reduction of melanosome level Tissue
1633 Increase in inflammation Increase in inflammation Tissue
1639 Plasma RA level decreased Plasma RA Tissue
1642 Decreased plasma RA level plasma retionic acid Tissue
1650 Epithelial-mesenchymal transition Epithelial-mesenchymal transition Tissue
1651 Treatment-resistant gastric cancer Resistant gastric cancer Tissue
1662 Increased plasma Homocysteine level plasma homocysteine increases Tissue
1665 Increased, Plasma HCY level Plasma HCY level Tissue
1674 Alveolar reopening Alveolar reopening Tissue
1675 Loss of barrier function Loss of barrier function Tissue
1683 Impairment, Fourth pharyngeal arch development Impairment, Fourth pharyngeal arch development Tissue
1688 anogenital distance (AGD), decreased AGD, decreased Tissue
1690 Decrease, testosterone levels Decrease, testosterone levels Tissue
1693 Reduction, Plasma progesterone concentration Reduction, Plasma progesterone concentration Tissue
1741 Induced, Angiotensin (Ang) II accumulation Induced, Angiotensin (Ang) II accumulation Tissue
1743 Increase plasma Ang II Increase plasma Ang II Tissue
1750 Increased inflammatory immune responses Increased inflammatory immune responses Tissue
1756 Decreased, plasma 11-ketotestosterone level Decreased, 11KT Tissue
1761 Inhibition, Fin regeneration Inhibition, Fin regeneration Tissue
1768 Increase, Abnormal osmoregulation Increase, Abnormal osmoregulation Tissue
1769 Increase, Body fluid overload Increase, Body fluid overload Tissue
1772 Decrease, Neutral lipids Decrease, Neutral lipids Tissue
1790 Increased, Differentiation to Testis Increased, Differentiation to Testis Tissue
1836 Decreased plasma Cortisol level Decreased plasma Cortisol level Tissue
1849 Impaired gustatory nerve Impaired gustatory nerve Tissue
1852 Increased Ang II type 1 receptor (AT1R) Increased Ang II type 1 receptor (AT1R) Tissue
1855 Increased Sodium-sensitive hypertension Increased Sodium-sensitive hypertension Tissue
1856 Imbalanced salty and sweet taste responses Sodium inhibition, Sweet enhancement Tissue
1868 Hyperinflammation Hyperinflammation Tissue
1872 Olfactory epithelium degeneration Olfactory epithelium degeneration Tissue
1877 Altered, retinal layer structure Altered, retinal layer structure Tissue
1881 Decreased, all-trans retinoic acid (atRA) concentration Decreased, atRA concentration Tissue
1888 Increased (ectopic) all-trans retinoic acid concentration increased atRA concentration Tissue
1891 abnormal, placental labyrinth vasculature morphology abnormal, placental labyrinth vasculature morphology Tissue
1898 increased release of danger/damage associated molecular patterns increased release of DAMPS Tissue
1907 Airway Surface Liquid Height, Decreased ASL Height, Decreased Tissue
1919 Increased,Cardiac Dysregulation Increased,Cardiac dysfunction Tissue
1926 Increased,Vascular fibrosis Increased,Vascular fibrosis Tissue
1928 increased,Vascular endothelial dysfunction increased,Vascular endothelial dysfunction Tissue
1960 Inhibition of Ikr Inhibition of Ikr Tissue
1988 Decreased, Maturation Inducing Steroid Surge by Granulosa cells Decreased, Maturation Inducing Steroids Surge by Granulosa cells Tissue
1989 Impaired, Oocyte maturation and ovulation Impaired, Oocyte maturation and ovulation Tissue
1990 Increased, Oocyte Atresia Increased, Oocyte Atresia Tissue
2035 development, liver cancer development, liver cancer Tissue
2041 Decrease, palatal shelf outgrowth Decrease, outgrowth Tissue
2060 Decrease, Chitin laminar organization Decrease, Chitin laminar organization Tissue
2061 Decrease, Prevent chitin degradation by chitinases Decrease, Prevent chitin degradation by chitinases Tissue
2068 Increase, Endothelial Dysfunction Increase, Endothelial Dysfunction Tissue
2076 Increase, hemocyanin mRNA Increase, hemocyanin mRNA Tissue
2084 Increase, Cardiac remodelling Increase, Cardiac remodelling Tissue
2090 Increase, Bone Remodeling Bone Remodeling Tissue
2096 Occurrence, (Micro)vascular dysfunction (Micro)vascular dysfunction Tissue
2097 Increase, Pro-Inflammatory Mediators Increase, Pro-Inflammatory Mediators Tissue
2098 Increase, Abnormal Neural Remodeling Abnormal Neural Remodeling Tissue
2107 Hypomyelination Hypomyelination Tissue
2108 Altered, white brain matter Altered, white brain matter Tissue
2136 prostatic intraepithelial neoplasia prostatic intraepithelial neoplasia Tissue
2137 Increase, Gonadotropins concentration in plasma Increase, Gonadotropins concentration in plasma Tissue
2138 Reduction,Testosterone concentration in plasma Reduction,Testosterone concentration in plasma Tissue
2178 Vascular barrier disruption Vascular barrier disruption Tissue
2179 Impaired Platelet Aggregation Impaired Platelet Aggregation Tissue
2206 Increased, histomorphological alteration of testis Increased, histomorphological alteration of testis Tissue
2210 Reduced cortical thickness Reduced cortical thickness Tissue